

# 第3日

D A Y 3

3月8日(土)

Saturday, March 8, 2025

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)

## Presidential Session

- PS4** Hepatobiliary / Pancreatic Cancer, Rare Cancer, Breast Cancer  
肝胆膵 希少がん 乳腺 ..... 277

## Joint Symposium

- JS7** Radiation therapy for Oligometastasis  
オリゴ転移に対する放射線治療 ..... 289
- JS8** Using Digital Technology in Supportive and Palliative Care for Cancer  
デジタル技術をがんの支持緩和医療に活かす ..... 293

## Presidential Symposium

- PSY5** Hereditary tumors in rare cancers  
希少がんの遺伝性腫瘍 ..... 279
- PSY6** Cancer gene panel testing should be performed before the primary treatment?  
がん遺伝子パネル検査は1次治療開始前に実施するべきか? ..... 280
- PSY7** New molecular-targeted therapy for colorectal cancers  
大腸がんに対する新たな分子標的治療薬 ..... 283

## Symposium

- SY19** Not too little, not too much : Optimizing more vs. less treatment for older patients  
with breast cancer  
高齢者早期乳癌における最適な治療は何か? 手術、放射線、薬物療法 ..... 279
- SY20** New treatments on the horizon for the upper GI cancers  
上部消化管癌に対する新規治療 ..... 281
- SY21** Clinical application of AI to Cancer Research & Care  
がん研究・診療へAIの応用 ..... 282
- SY22** Development of new technologies for lung cancer  
肺癌治療・診断の新たな技術開発 ..... 283
- SY23** Treatment strategy for mRCC 2025: Is HIF-2  $\alpha$  inhibitor a game changer?  
進行性腎細胞がんの治療戦略 2025: HIF-2  $\alpha$  阻害薬は game changer か? ..... 284
- SY24** Management of Chemotherapy-induced peripheral neuropathy  
化学療法誘発性末梢神経障害のマネジメント ..... 285
- SY25** Optimization of long-term health management of childhood and adolescent cancer  
survivors: how can we support their transition to adult care?  
小児・思春期世代がん経験者の移行期支援について考える ..... 287
- SY26** "Focused"/"Spotlighted" Early Phase 1 Oncology Drug Development 2025  
がん新薬早期開発 2025 "Focused"/"Spotlighted" Early Phase Drug Development ..... 292
- SY27** Current state and future direction of immunotherapies in malignant lymphoma and  
multiple myeloma  
リンパ腫・骨髄腫に対する新たな免疫治療 ..... 292

<b>SY28</b>	Current updates to learn about clinical trial modernization いま学ぶべき臨床試験の適正化・効率化に向けた最新知見 .....	294
<b>SY29</b>	Rare cancers with promising drugs in the future 希少がんに対する今後有望となる薬剤 .....	294
<b>SY30</b>	Future outlook on MRD testing in peri-operative clinical trials MRD 検査が切り拓く周術期試験デザインの近未来 .....	295

#### Meet the Experts

<b>ME12</b>	New Phase in Brain Tumor Treatment - Precision Therapy, Gene Therapy, International Collaboration 脳腫瘍治療の新フェーズ—Precision Therapy、遺伝子治療、国際コラボレーション .....	314
<b>ME13</b>	Patient-Centered Care for adolescents and young adults with cancer .....	314
<b>ME14</b>	Challenges with biomarker-based therapy development .....	314
<b>ME15</b>	State of the art, perspectives and challenges in NSCLC oncogene addiction .....	315
<b>ME16</b>	Future of metastatic prostate cancer .....	315
<b>ME17</b>	The career development of female oncologists in the United States .....	315

#### Highlight of the Day

<b>HoD3</b>	Highlight of the Day 3 .....	278
-------------	------------------------------	-----

## 第1会場 (神戸ポートピアホテル 南館1階 ポートピアホール)

8:30-11:10 Presidential Session 4

**PS4** Hepatobiliary / Pancreatic Cancer, Rare Cancer, Breast Cancer  
肝胆腫瘍 希少がん 乳腺

**E L O**

- Chairs :** Masafumi Ikeda (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East)  
Zev Wainberg (Department of Medicine, UCLA School of Medicine, Los Angeles, California)
- Discussants :** Li-Tzong Chen (Department of Internal Medicine, Kaohsiung Medical University Hospital and Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan)  
Stephen Lam Chan (The Chinese University of Hong Kong)  
Hiroyuki Okuyama (Department of Medical Oncology, Kagawa University Hospital)  
Aleix Prat (Clinic Barcelona Comprehensive Cancer Center)
- 司会 :** 池田 公史 (国立がん研究センター東病院 肝胆腫瘍内科)  
Zev Wainberg (Department of Medicine, UCLA School of Medicine, Los Angeles, California)
- ディスカッサント :** Li-Tzong Chen (Department of Internal Medicine, Kaohsiung Medical University Hospital and Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan)  
Stephen Lam Chan (The Chinese University of Hong Kong)  
奥山 浩之 (香川大学医学部附属病院)  
Aleix Prat (Clinic Barcelona Comprehensive Cancer Center)

### PS4-1 First-line Treatment for Hepatocellular Carcinoma with a CRAFTY Score of 2: Comparison of Lenvatinib and Immunotherapy

Masayuki Ueno (Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University)

**CRAFTY スコア 2 点の肝細胞癌に対する一次薬物療法 : レンバチニブと免疫療法の治療効果の比較**

上野 真行 (京都大学大学院医学研究科 消化器内科学)

### PS4-2 Final Results of TCOG T5217 Trial: SLOG vs Modified FOLFIRINOX as First-Line Treatment in Advanced Pancreatic Cancer

Yung-yeh Su (Stanford Cancer Institute)

### PS4-3 A phase III study of everolimus/lanreotide versus everolimus for gastroenteropancreatic neuroendocrine tumor (JCOG1901)

**Encore**

Hidekazu Hirano (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)

**消化管・脾原発の切除不能進行・再発神経内分泌腫瘍に対するエベロリムス単剤療法とエベロリムス + ランレオチド併用療法のランダム化第III相試験 : JCOG1901**

平野 秀和 (国立がん研究センター中央病院)

### PS4-4 T-DXd in HER2+ advanced/metastatic breast cancer patients with/without brain metastases: results from DESTINY-Breast12

**Encore**

Naoki Niikura (Tokai University School of Medicine, Kanagawa, Japan)

**脳転移を伴う又は伴わない治療歴のある HER2 陽性の進行 / 転移性乳癌患者を対象とするトラスツズマブ デルクステカンの試験結果 (DESTINY-Breast12)**

新倉 直樹 (Tokai University School of Medicine, Kanagawa, Japan)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

15:00-16:30 Highlight of the Day 【泌尿器、頭頸部、TR・臨床薬理、肝胆膵、希少がん、乳腺】 / Highlight of the Day 【Urological Oncology / Head and Neck Cancer / Translational Research/Clinical Pharmacology / Hepatobiliary and Pancreatic Oncology / Rare Cancer / Breast cancer】

**HoD3 Highlight of the Day 3** 

Chairs : Koji Iwata (Department of Advanced Clinical Research and Development, Nagoya City University, Graduate School of Medical Sciences)  
 Tetsuji Takayama (Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences)  
 司会 : 岩田 広治 (名古屋市立大学大学院医学研究科 臨床研究戦略部 先端医療・臨床研究開発学分野)  
 高山 哲治 (徳島大学大学院医歯薬学研究部消化器内科学分野)

Hod3-1 Koji Izumi (Integrative Cancer Therapy and Urology, Kanazawa University)  
 泉 浩二 (金沢大学 泌尿器集学的治療学)

Hod3-2 Yosuke Togashi (Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences (Medicine), Okayama University/Department of Allergy and Respiratory Medicine, Okayama University Hospital)  
 富樫 庸介 (岡山大学学術研究院医歯薬学域 腫瘍微小環境学分野 / 岡山大学病院 呼吸器・アレルギー内科)

Hod3-3 Masafumi Ikeda (Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East)  
 池田 公史 (国立がん研究センター東病院 肝胆膵内科)

Hod3-4 Yoshifumi Kida (Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences)  
 喜田 慶史 (徳島大学大学院医歯薬学研究部 消化器内科学分野)

Hod3-5 Fumikata Hara (Department of Breast Oncology, Aichi Cancer Center)  
 原 文堅 (愛知県がんセンター 乳腺科)

Hod3-6 Tomoya Yokota (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)  
 横田 知哉 (静岡県立静岡がんセンター 消化器内科・新規治療開発科)

## 第2会場 (神戸ポートピアホテル 南館1階 大輪田A)

8:30-10:00 Symposium 19 / シンポジウム 19

**SY19** Not too little, not too much : Optimizing more vs. less treatment for older patients with breast cancer  
高齢者早期乳癌における最適な治療は何か? 手術、放射線、薬物療法



Chairs : Hiroshi Ishiguro (Saitama Medical University International Medical Center)  
Giuseppe Curigliano (European Institute of Oncology, IRCCS and University of Milano)  
Panelists: Yasuaki Sagara (Department of Breast and Thyroid Surgical Oncology, Sagara Hospital)  
Akihiko Shimomura (National Center for Global Health and Medicine)  
Yuichiro Kikawa (Department of Breast Surgery, Kansai Medical University)

司会 : 石黒 洋 (埼玉医科大学国際医療センター)  
Giuseppe Curigliano (European Institute of Oncology, IRCCS and University of Milano)

パネリスト: 相良 安昭 (相良病院 乳腺甲状腺外科)  
下村 昭彦 (国立国際医療研究センター病院 がん総合内科 / 乳腺・腫瘍内科)  
木川雄一郎 (関西医科大学 乳腺外科)

**SY19** < Keynote Lecture / 基調講演 >

**Not too little, not too much: optimizing more versus. less treatment for older patients with breast cancer.**

Etienne Brain (Institut Curie and UVSQ)

10:10-11:40 Presidential Symposium 5 / 会長企画シンポジウム 5

**PSY5** Hereditary tumors in rare cancers  
希少がんの遺伝性腫瘍



Chairs : Akihiro Sakurai (Department of Medical Genetics and Genomics, Sapporo Medical University School of Medicine)  
Makoto Hirata (Department of Genetic Medicine and Services, National Cancer Center Hospital)

司会 : 櫻井 晃洋 (札幌医科大学 遺伝医学)  
平田 真 (国立がん研究センター 中央病院 遺伝子診療部門)

**PSY5-1** Clinical practice and perspectives on hereditary breast and ovarian cancer for breast cancer oncologists

Masahiko Tanabe (The Department of Breast and Endocrine Surgery, The University of Tokyo Hospital)

**遺伝性乳癌卵巣癌診療の実際と展望～乳癌治療医の立場から～**

田辺 真彦 (東京大学医学部附属病院 乳腺内分泌外科)

**PSY5-2** Current and past treatment strategies for Von Hippel-Lindau (VHL) disease in Japan

Eijiro Nakamura (National Cancer Center Hospital Japan)

**本邦における Von Hippel-Lindau(VHL 病) に対する診療の取り組みと変遷**

中村 英二郎 (国立がん研究センター中央病院)

**PSY5-3** Mucocutaneous Lesions of Cowden Syndrome

Yoshiaki Kubo (Department of Dermatology, Tokushima University Graduate School of Medical Science)

**Cowden 症候群の皮膚粘膜病変**

久保 宜明 (徳島大学大学院医歯薬学研究所 皮膚科学分野)

**PSY5-4** Li-Fraumeni syndrome surveillance and cancer treatment

Hiro Yoshi Hattori (Department of Clinical Genetics, NHO Nagoya Medical Center)

**Li-Fraumeni 症候群のサーベイランスとがん診療**

服部 浩佳 (国立病院機構名古屋医療センター 遺伝診療科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

PSY5-5 **Current status and latest information on medical management of Lynch syndrome**  
Takeshi Nakajima (Osaka International Cancer Institute)  
**リンチ症候群の診療の現状と最新情報について**  
中島 健 (大阪国際がんセンター)

14:00-15:30 Presidential Symposium 6 / 会長企画シンポジウム 6

**PSY6** Cancer gene panel testing should be performed before the primary treatment?  
がん遺伝子パネル検査は1次治療開始前に実施するべきか? **LO**

Chairs : Eishi Baba (Department of Comprehensive Oncology, Kyushu University)  
Manabu Muto (Department of Medical Oncology, Kyoto University Graduate School of Medicine)  
司会 : 馬場 英司 (九州大学大学院医学研究院 連携腫瘍学)  
武藤 学 (京都大学大学院医学研究科 腫瘍内科学講座)

PSY6-1 **Multicenter clinical trial to evaluate the utility of CGP prior to initial systemic therapy in advanced solid tumors (NCCH1908:UPFRONT trial)**  
Takaaki Mizuno (Department of Experimental Therapeutics, National Cancer Center Hospital/ Genomics Unit, Keio Cancer Center, Keio University School of Medicine)  
**固形がん患者における初回治療時の包括的ゲノムプロファイル (CGP) 検査の実現性と治療選択への有用性を評価する多施設共同前向き研究 (NCCH1908:UPFRONT 試験)**  
水野 孝昭 (国立がん研究センター中央病院 先端医療科 / 慶應大学腫瘍センター がんゲノム医療ユニット)

**PSY6-2** **The first-line comprehensive genomic profiling of advanced solid tumors: 1-year follow-up data of the FIRST-Dx study**  
Junichi Matsubara (Department of Medical Oncology, Kyoto Univ. Graduate School of Medicine)  
**先進医療 B: 標準治療前のがん遺伝子パネル検査の有用性を評価する多施設共同前向き研究 FIRST-Dx study の1年フォローアップデータ**  
松原 淳一 (京都大学大学院医学研究科 腫瘍内科学)

PSY6-3 **The significance and optimal timing of comprehensive genomic profiling test in patients with metastatic breast cancer**  
Ipei Fukada (Genomic Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research)  
**転移再発乳がん患者における遺伝子パネル検査の意義と最適な実施タイミングを考える**  
深田 一平 (がん研究会有明病院 ゲノム診療部)

PSY6-4 **Should cancer gene panel testing be carried out before starting the first-line treatment for patients with mCRPC?**  
Hiroshi Kitamura (Department of Urology, Faculty of Medicine, University of Toyama)  
**前立腺がんに対するがん遺伝子パネル検査の現在地と向かうべき道**  
北村 寛 (富山大学学術研究部医学系 腎泌尿器科学)

PSY6-5 **Promotion of Cancer Genomic Medicine in Japan**  
Shinya Tsuruta (Cancer and Disease Control Division, Public Health Bureau, Ministry of Health, Labour and Welfare, Government of Japan)  
**ゲノム医療の推進について**  
鶴田 真也 (厚生労働省 健康・生活衛生局 がん・疾病対策課)

## 第3会場 (神戸ポートピアホテル 南館1階 大輪田B)

8:30-9:30 Oral Session 15

### O15 Gastrointestinal Cancer 2 消化管 2

E

Chairs : Yasuo Hamamoto (Department of Medical Oncology, Institution of Science Tokyo)  
Ken Kato (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)  
Discussants : Masahiro Hirakawa (Department of Gastroenterology, Hokkaido Cancer Center)  
Daisuke Kotani (Department of gastrointestinal oncology, National Cancer Center Hospital East)  
司会 : 浜本 康夫 (東京科学大学)  
加藤 健 (国立がん研究センター中央病院)  
ディスカッション : 平川 昌宏 (国立病院機構北海道がんセンター 消化器内科)  
小谷 大輔 (国立がん研究センター東病院)

### O15-1 Phase 2 trial of ramucirumab plus docetaxel as second-line treatment for advanced gastric cancer (HGCSG 1903)

Masayoshi Dazai (Department of Gastroenterology, Sapporo Medical Center NTT EC)

切除不能進行 / 再発胃癌に対する二次治療ラムシルマブ + ドセタキセル療法の第II相試験 (HGCSG1903)

太宰 昌佳 (NTT 東日本札幌病院 消化器内科)

### O15-2 Sotorasib, panitumumab and FOLFIRI in the first-line with KRAS G12C-mutated mCRC: Safety and efficacy from CodeBreak 101

Encore

Toshiki Masuishi (Aichi Cancer Center Hospital)

KRAS G12C 変異を有する切除不能大腸癌に対するソトラシブ、パニツムマブ及びFOLFIRIを併用した一次治療の有効性及び安全性 (CodeBreak 101 試験)

Toshiki Masuishi (Aichi Cancer Center Hospital)

### O15-3 ctDNA for predicting response after Total Neoadjuvant Therapy for rectal cancer - Results from ENSEMBLE-2 study -

Encore

Koji Ando (Department of Surgery and Science, Kyushu University)

直腸癌に対する total neoadjuvant therapy の効果を予測するための ctDNA 検査 -ENSEMBLE-2 試験の結果から -

安藤 幸滋 (九州大学大学院 消化器・総合外科)

10:10-11:40 Symposium 20 / シンポジウム 20

### SY20 New treatments on the horizon for the upper GI cancers 上部消化管癌に対する新規治療

E O

Chairs : Daisuke Takahari (Department of Medical Oncology, Gunma University Graduate School of Medicine)  
Hanneke W.M. van Laarhoven (Department of Medical Oncology, Amsterdam UMC)  
司会 : 高張 大亮 (群馬大学 大学院医学系研究科 内科学講座 腫瘍内科学分野)  
Hanneke W.M. van Laarhoven (Department of Medical Oncology, Amsterdam UMC)

### SY20-1 New HER2 - Targeted Therapies

Sylvie Lorenzen (Department of Hematology and Oncology, Klinikum rechts der Isar)

### SY20-2 Claudin-18.2 as a new therapeutic target in upperGI cancer

Hanneke W.M. van Laarhoven (Department of Medical Oncology, Amsterdam UMC)

### SY20-3 Expanding the horizon of immunotherapy combinations in mismatch repair proficient advanced gastric cancer

Ian Chau (Royal Marsden Hospital)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

SY20-4 **Treatment Strategies for MSI-H Gastric Cancer**  
Yukiya Narita (Department of Clinical Oncology, Aichi Cancer Center Hospital)

**MSI-H 胃癌に対する治療戦略**  
成田 有季哉 (愛知県がんセンター 薬物療法部)

SY20-5 **The recent trend of early-development trials in Upper Gastrointestinal Cancers**  
Shigehiro Koganemaru (Department of Experimental Therapeutics, National Cancer Center Hospital East)

**上部消化管がんの早期開発試験における最近の傾向と今後の展望**  
小金丸 茂博 (国立がん研究センター東病院 先端医療科)

14:00-16:30 Symposium 21 / シンポジウム 21

**SY21 Clinical application of AI to Cancer Research & Care**  
がん研究・診療へ AI の応用



Chairs : Maki Tanioka (Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine)  
Kenji Hirata (Department of Diagnostic Imaging, Faculty of Medicine, Hokkaido University)

司会 : 谷岡 真樹 (岡山大学大学院医歯薬学総合研究科)  
平田 健司 (北海道大学 大学院医学研究院 画像診断学教室)

SY21-1 **Reporting patient summaries from electronic medical records using large-scale language models and generative AI**  
Gen Tamiya (Tohoku University School of Medicine/RIKEN Center for Advanced Intelligence Project)

**大規模言語モデルと生成 AI を用いた電子カルテからの患者サマリー作成**  
田宮 元 (東北大学大学院医学系研究科 / 理化学研究所革新知能統合研究センター)

SY21-2 **An Explainable Deep Learning Model and Spatial Gene Expression Platform to Discover Novel Drug Targets for Anti-cancer drugs**  
Maki Tanioka (Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine)

**説明可能深層学習と空間的遺伝子発現を融合した薬剤の新規創薬標的の同定**  
谷岡 真樹 (岡山大学大学院医歯薬学総合研究科)

SY21-3 **Biological feature extraction of histopathology images for multimodal analysis**  
Shumpei Ishikawa (Department of Preventive Medicine, Graduate School of Medicine, The University of Tokyo / Division of Pathology, Exploratory Oncology Research & Clinical Trial Center Pathology, National Cancer Center)

**マルチモデル解析のための病理組織画像の生物学的特徴抽出**  
石川 俊平 (東京大学大学院 医学系研究科 衛生学分野 / 国立がん研究センター 先端医療開発センター 臨床腫瘍病理分野)

SY21-4 **Clinical Application of Medical AI: Focusing on the research and development of AI-based medical devices**  
Ryuji Hamamoto (National Cancer Center Research Institute)

**医療 AI の実臨床応用 : AI を活用したプログラム医療機器の研究開発を中心として**  
浜本 隆二 (国立がん研究センター)

SY21-5 **Support System for Cytodiagnosis Using Artificial Intelligence for 3D Image Recognition**  
Ken'ichi Morooka (Faculty of Advanced Science and Technology, Kumamoto University)

**3D 画像認識 AI による癌診断支援システム**  
諸岡 健一 (熊本大学 大学院先端科学研究部)



## 第4会場 (神戸ポートピアホテル 南館1階 大輪田C)

8:30-10:00 Presidential Symposium 7 / 会長企画シンポジウム 7

**PSY7** New molecular-targeted therapy for colorectal cancers  
大腸がんに対する新たな分子標的治療薬

**E O**

Chairs : Takayuki Yoshino (National Cancer Center Hospital East)  
Kei Muro (Department of Clinical Oncology, Aichi Cancer Center Hospital)  
司会 : 吉野 孝之 (国立がん研究センター東病院)  
室 圭 (愛知県がんセンター 薬物療法科)

**PSY7-1** Tucatinib plus trastuzumab for HER2-positive, RAS wild-type metastatic colorectal cancer

**Encore**

John H. Strickler (Duke University, Duke Cancer Institute)

**PSY7-2** Trastuzumab-Deruxtecan for HER2 positive colorectal cancer

Hisato Kawakami (Department of Clinical Oncology, Tohoku University Graduate School of Medicine)

**HER2 陽性大腸癌に対するトラスツズマブデルクステカン**

川上 尚人 (東北大学大学院 医学系研究科 臨床腫瘍学分野)

**PSY7-3** Sotorasib Plus Panitumumab for Colorectal Cancer with KRAS G12C Mutation

Tae Won Kim (Asan Medical Center)

**PSY7-4** New treatment option for salvage line colorectal cancer: Fruquintinib

Taroh Satoh (Center for Cancer Genomics and Precision Medicine, Osaka University Hospital)

**大腸がんサルベージラインにおける新たな選択肢：フルキンチニブ**

佐藤 太郎 (大阪大学医学部附属病院 がんゲノム医療センター)

**PSY7-5** Optimal therapy to target BRAF mutated colorectal cancer

Kopetz Scott (The University of Texas MD Anderson Cancer Center)

10:10-11:40 Symposium 22 / シンポジウム 22

**SY22** Development of new technologies for lung cancer  
肺癌治療・診断の新たな技術開発

**E O**

Chairs : Hidetoshi Hayashi (Department of Medical Oncology, Kindai University Faculty of Medicine)  
Motoko Tachihara (Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine)

司会 : 林 秀敏 (近畿大学医学部内科学腫瘍内科)  
立原 素子 (神戸大学大学院医学研究科内科学講座呼吸器内科学分野)

**SY22-1** ADC/Bi-specific Antibody

Byoung Chul Cho (Yonsei Cancer Center, Yonsei University College of Medicine)

**SY22-2** Advances in DLL3-Targeted T-Cell Engagers: Revolutionizing Therapy for Small-Cell Lung Cancer and Neuroendocrine Tumors

Tatsuya Yoshida (Department of Thoracic Oncology/Experimental Therapeutics, National Cancer Center Hospital)

**二重特異性T細胞誘導抗体による新たな治療戦略：小細胞肺癌および神経内分泌腫瘍における治療の進展**

吉田 達哉 (国立がん研究センター中央病院 呼吸器内科 / 先端医療科)

**SY22-3** TTF1 Therapy in NSCLC

Ticiania Leal (Emory University)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

SY22-4 **Innovative Approaches in Pathological Assessment**  
Takuo Hayashi (Department of Human Pathology, Juntendo University School of Medicine)

**病理診断における革新的なアプローチ - 手**  
林 大久生 (順天堂大学医学部人体病理病態学講座)

SY22-5 **State-of-the-Art Lung Cancer Imaging**  
Yoshiharu Ohno (Department of Diagnostic Radiology, Fujita Health University School of Medicine)

**肺癌における最新画像診断**  
大野 良治 (藤田医科大学 医学部 放射線診断学講座)

14:00-15:30 Symposium 23 / シンポジウム 23

**SY23** Treatment strategy for mRCC 2025: Is HIF-2 $\alpha$  inhibitor a game changer?  
進行性腎細胞がんの治療戦略 2025: HIF-2 $\alpha$ 阻害薬は game changer か? **E O**

Chairs : Thomas Powles (Centre for Experimental Cancer Medicine, Barts Cancer Institute)  
Masayuki Takahashi (Department of Urology, Takamatsu Municipal Hospital)

Oversight by the Chair : Thomas Powles (Centre for Experimental Cancer Medicine, Barts Cancer Institute)  
司会 : Thomas Powles (Centre for Experimental Cancer Medicine, Barts Cancer Institute)  
高橋 正幸 (高松市立みんなの病院 泌尿器科)

総括 : Thomas Powles (Centre for Experimental Cancer Medicine, Barts Cancer Institute)

SY23-1 **The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in modern era**  
Ken-ichi Tabata (Department of Urology, Kitasato University Kitasato Insititute Hospital)

**mRCC に対する腎摘除術 ;TKI, ICI 時代における役割**  
田畑 健一 (北里大学北里研究所病院 泌尿器科)

SY23-2 **Treatment strategy for mRCC: Is HIF-2 $\alpha$  inhibitor a game changer?**  
Ravindran Kanesvaran (National Cancer Centre Singapore)

SY23-3 **Combined immunotherapy for advanced renal cell carcinoma. When IO/IO and when IO/TKI?**  
Kohji Takemura (Department of Medical Oncology, Toranomon Hospital)

**進行腎細胞癌に対する免疫チェックポイント阻害薬併用療法の臨床応用**  
竹村 弘司 (虎の門病院 臨床腫瘍科)

SY23-4 **HIF-2 Alpha Inhibitors - Game Changers?**  
Eric Jonasch (UT MD Anderson Cancer Center)

## 第5会場 (神戸ポートピアホテル 南館 B1階 トパース)

8:30-10:00 Symposium 24 / シンポジウム 24

### SY24 Management of Chemotherapy-induced peripheral neuropathy 化学療法誘発性末梢神経障害のマネジメント



Chairs : Kazuhiro Yanagihara (Department of Medical Oncology, Kansai Electric Power Hospital)  
Tomohiro Inui (Cancer Management Center, Tokushima University Hospital)

司会 : 柳原 一広 (関西電力病院 腫瘍内科)  
乾 友浩 (徳島大学病院 がん診療連携センター)

#### SY24-1 Strategies and research for the prevention of chemotherapy-induced peripheral neuropathy

Akiko Hanai (Chiba University Faculty of Informatics)

##### 化学療法誘発性末梢神経障害の予防戦略とその研究開発

華井 明子 (千葉大学大学院 情報学研究院)

#### SY24-2 Management of Chemotherapy Induced Peripheral Neuropathy -Evidence for Drug Therapy-

Yoichiro Yoshida (Center for Medical Informatics and Data Science, Fukuoka University Hospital)

##### 化学療法誘発性末梢神経障害のマネジメント -薬物療法のエビデンス-

吉田 陽一郎 (福岡大学病院 医療情報・データサイエンスセンター 消化器外科)

#### SY24-3 Efficacy of acupuncture for Chemotherapy-Induced Peripheral Neurotoxicity in breast cancer survivors

Hiroto Ishiki (Department of Palliative Medicine, National Cancer Center Hospital)

##### 乳がんサバイバーの化学療法誘発性末梢神経障害に対する鍼灸治療の開発

石木 寛人 (国立がん研究センター中央病院 緩和医療科)

#### SY24-4 Medical devices for chemotherapy-induced peripheral neuropathy

Emi Kubo (National Cancer Center Hospital East)

##### 化学療法誘発性末梢神経障害に対する医療機器

久保 絵美 (国立がん研究センター東病院)

#### SY24-5 Management of chronic cancer pain involving nociplastic pain

Toshiari Kawai (Department of Psycho-Oncology, Cancer Institute Hospital of JFCR)

##### 痛覚変調性疼痛が関与するがん性慢性疼痛のマネジメント

川居 利有 (公益財団法人がん研究会 有明病院 腫瘍精神科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

10:10-11:30 Oral Session 16

**016** Palliative Care / Symptom Management  
緩和ケア・支持療法



Chairs : Yasuhito Terui (Department of Hematology, Saitama Medical University)  
Akihito Tsuji (Department of Clinical Oncology, Kagawa University Faculty of Medicine)  
Discussants : Hideki Katayama (Department of Palliative and Supportive Care, Okayama University Hospital)  
Tomofumi Miura (Department of Palliative Medicine, National Cancer Center Hospital East)  
司会 : 照井 康仁 (埼玉医科大学 血液内科)  
辻 晃仁 (香川大学医学部臨床腫瘍学講座)  
ディスカッサント : 片山 英樹 (岡山大学病院 緩和支援医療科)  
三浦 智史 (国立がん研究センター東病院)

**016-1** **A mobile app-based program for facilitating advance care planning discussions between patients and oncologists**

**Encore**  
Kyoko Obama (Institute for Cancer Control, National Cancer Center)  
**アプリケーションを用いた治療やケアについての進行がん患者と医師との協働意思決定支援の有効性評価**  
小濱 京子 (国立研究開発法人国立がん研究センター)

**016-2** **A prospective RCT of prehabilitation intervention during preoperative chemotherapy in elderly esophageal cancer patients**

Keijiro Sugimura (Kansai Rosai Hospital)  
**高齢食道癌患者における術前化療中の栄養リハビリ介入前向きランダム化比較試験**  
杉村 啓二郎 (関西労災病院)

**016-3** **Utilizing natural language processing to identify and visualize adverse events in cancer patients from medical notes**

Masami Tsuchiya (Division of Drug Informatics, Keio University Faculty of Pharmacy)  
**自然言語処理を用いた診療テキストデータからのがん薬物療法副作用の検出と経時的可視化手法**  
土屋 雅美 (慶應義塾大学薬学部)

**016-4** **Real-world data of anamorelin in 7,132 patients with cancer cachexia: An interim analysis of post-marketing surveillance**

Kazuo Tamura (Clinical Hematology Oncology Treatment Study Group)  
**がん悪液質患者 7,132 例におけるアナモレリンのリアルワールドデータ：特定使用成績調査の中間解析**  
田村 和夫 (臨床血液・腫瘍研究会)

SY25

Optimization of long-term health management of childhood and adolescent cancer survivors:  
how can we support their transition to adult care?  
小児・思春期世代がん経験者の移行期支援について考える



Chairs : Chikako Shimizu (Department of Breast and Medical Oncology, National Center for Global Health and Medicine)  
Hatoe Sakamoto (National Cancer Center Hospital East)

Special Remarks : Yuka Kato (Department of Nursing, Shizuoka Children Hospital)

Commentator : Bradley J. Zebrack (University of Michigan Rogel Cancer Center and School of Social Work)

司会 : 清水 千佳子 (国立国際医療研究センター病院 乳腺・腫瘍内科)

坂本 はと恵 (国立研究開発法人国立がん研究センター東病院)

特別発言: 加藤 由香 (地方独立行政法人静岡県立病院機構 静岡県立こども病院 看護部)

コメンテーター: Bradley J. Zebrack (University of Michigan Rogel Cancer Center and School of Social Work)

SY25-1 **My utilization of long-term follow up and primary care - From the perspective of a childhood cancer survivor-**

Daisuke Masumoto (Childhood Cancer Association in Japan)

**長期フォローアップとプライマリケアの活用 - 小児がん経験者の立場から -**

舩本 大輔 (公益財団法人がんの子どもを守る会)

SY25-2 **Challenges of Transitional Support for Childhood Cancer Survivors**

Kimikazu Matsumoto (Children's Cancer Center, National Center for Child Health and Development)

**小児がん経験者の移行期支援の課題**

松本 公一 (国立成育医療研究センター 小児がんセンター)

SY25-3 **Approaches to Transition Support in Adult Health Care -NCGM Transition Care Program-**

Tomoko Taniyama (National Center for Global Health and Medicine)

**成人医療における移行支援の取り組みー NCGM 移行支援プログラムについてー**

谷山 智子 (国立国際医療研究センター病院)

SY25-4 **Building partnerships between cancer centers and local medical institutions for long-term health management of cancer survivors**

Satoshi Kanke (Department of General Internal Medicine and Family Medicine, Fukushima Medical University)

**サイバーの健康管理における拠点病院と地域医療機関の連携構築**

菅家 智史 (福島県立医科大学医学部総合内科・総合診療学講座)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Room 14  
Meet the Experts  
Poster

15:30-16:30 Mini Oral Session 37

**MO37** Palliative Care / Symptom Management 3 (Symptom Management)  
緩和ケア・支持療法 3 (支持療法)

Chairs : Chiyo Kitagawa (NHO Nagoya Medical Center)  
Tomohiro Inui (Cancer Management Center, Tokushima University)  
司会 : 北川 智余恵 (NHO 名古屋医療センター 腫瘍内科)  
乾 友浩 (徳島大学病院 がん診療連携センター)

**MO37-1** Effect of antiemetic therapy with olanzapine on carboplatin-induced nausea and vomiting in patients with anorexia

Kazuki Tanaka (Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine)

カルボプラチン誘発性悪心・嘔吐に対するオランザピンを併用した制吐療法の食思不振に対する効果

田中 和樹 (浜松医科大学第二内科)

**MO37-2** Olanzapine-based triplet antiemetic therapy for patients undergoing trastuzumab deruxtecan: ERICA (WJOG14320B)

Hitomi Sakai (Advanced Cancer Translational Research Institute, Showa University)

トラスツズマブデルクステカン治療を受ける患者に対するオランザピン込みの3剤併用制吐療法:ERICA 試験 (WJOG14320B)

酒井 瞳 (昭和大学先端がん治療研究所)

**MO37-3** Quantitative Assessment of Edema Induced by Docetaxel in Breast Cancer Patients

Akiko Ota (TOYOTA Memorial Hospital, Department of Oncology)

乳癌患者におけるドセタキセルによる浮腫の定量的評価

大田 亜希子 (トヨタ記念病院 腫瘍内科)

**MO37-4** A prospective multicenter study of taste change after CHOP therapy in lymphoma

Tsutomu Takahashi (Department of Hematology, Shimane University Hospital)

リンパ腫に対するCHOP療法後の味覚変化:多施設前向き観察研究

高橋 勉 (島根大学医学部附属病院 血液内科)

**MO37-5** A randomized controlled trial to relieve distress of chemotherapy-induced peripheral neuropathy by magnetic field

Emi Kubo (National Cancer Center Hospital East)

化学療法誘発性末梢神経障害に対する交番磁界治療の探索的医師主導試験

久保 絵美 (国立がん研究センター東病院)

**MO37-6** Chemotherapy-induced peripheral neuropathy due to oxaliplatin and taxane: A post hoc analysis of the MiroCIP study

Sonoko Misawa (Department of Neurology, Graduate School of Medicine, Chiba University)

MiroCIP研究から見た実臨床におけるオキサリプラチンとタキサン系製剤による化学療法誘発性末梢神経障害の実態

三澤 園子 (千葉大学大学院 医学研究院 脳神経内科学)

## 第6会場 (神戸ポートピアホテル 南館 B1階 エメラルド)

8:30-10:30 Joint Symposium 7 (JASTRO / JSMO) /  
合同シンポジウム 7 (日本放射線腫瘍学会/日本臨床腫瘍学会)

### JS7 Radiation therapy for Oligometastasis オリゴ転移に対する放射線治療

Chairs : Hitoshi Ikushima (Department of Therapeutic Radiology, Tokushima University Graduate School)  
Sadamoto Zenda (Department of Radiation Oncology, National Cancer Center Hospital East)  
司会 : 生島 仁史 (徳島大学大学院 放射線治療学分野)  
全田 貞幹 (国立がん研究センター東病院 放射線治療科)

JS7-1 **Concept of oligometastasis and the effectiveness of local treatment**  
Katsuyuki Shirai (Department of Radiation Oncology, Jichi Medical University Hospital)  
**オリゴ転移の概念・局所治療の有効性**  
白井 克幸 (自治医科大学附属病院 放射線治療科)

JS7-2 **Stereotactic body radiotherapy for lung metastases**  
Yasuo Matsumoto (Department of Radiation Oncology, Niigata Cancer Center Hospital)  
**肺転移に対する体幹部定位放射線治療**  
松本 康男 (新潟県立がんセンター新潟病院 放射線治療科)

JS7-3 **Stereotactic Body Radiotherapy for oligo-bone metastases**  
Kei Ito (Department of Radiation Oncology, Tokyo Metropolitan Komagome Hospital)  
**オリゴ骨転移に対する定位放射線治療**  
伊藤 慶 (東京都立駒込病院 放射線科治療部)

JS7-4 **Follow-up and management after treatment for oligometastatic disease**  
Taiji Koyama (Medical Oncology/Hematology, Kobe University Hospital)  
**オリゴ転移治療後の経過観察と管理**  
小山 泰司 (神戸大学医学部附属病院 腫瘍・血液内科)

14:00-15:00 Mini Oral Session 38

### MO38 Gastrointestinal Cancer 4 (Esophageal Cancer 1) 消化管 4 (食道 1)

E

Chairs : Keiko Minashi (Clinical Trial Promotion department, Chiba Cancer Center)  
Takashi Kojima (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)  
司会 : 三梨 桂子 (千葉県がんセンター 治験臨床試験推進部)  
小島 隆嗣 (国立がん研究センター東病院 消化管内科)

MO38-1 **Effect of proton pump inhibitors use and predictors on first line treatment for recurrent/unresectable esophageal cancer**  
Junichiro Itani (Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine)  
**切除不能進行・再発食道癌に対する一次治療における効果予測因子とプロトンポンプ阻害薬の影響**  
伊谷 純一郎 (京都府立医科大学大学院医学研究科 消化器内科学)

MO38-2 **Clinical Significance of FGFRs in Esophageal Cancer: Potential Therapeutic Targets**  
Aprajita . (Guru Gobind Singh Indraprastha University, Dwarka , Delhi)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Poster Experts

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

MO38-3 **Exploring new ICI biomarkers and drug discovery potential in genomic variants of ESCC from over 1,000 Japanese cases**  
 Ryuichi Morita (Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine)  
**食道扁平上皮癌の遺伝子変異に見る、ICIの新たなバイオマーカーの探索と新薬開発の可能性:1000例以上の日本人データから**  
 森田 竜一 (京都府立医科大学大学院 医学研究科 消化器内科学)

MO38-4 **Denoised IMC reveals spatial dynamics of CD39+ exhausted T cells through TLS in anti-PD-1-treated esophageal cancer**  
 Kenro Tanoue (Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University)  
**抗PD-1抗体治療下食道癌におけるCD39陽性疲弊T細胞の3次リンパ組織媒介型空間動態を解明するDenoisingを施したイメージングマスマイトメトリー解析**  
 田ノ上 絢郎 (九州大学)

MO38-5 **Nivolumab combined with definitive chemoradiotherapy for esophageal squamous cell carcinoma : The NOBEL trial**  
 Akinori Watanabe (Department of Gastroenterology, Kitasato university school of medicine)  
**食道扁平上皮癌に対するニボルマブ併用根治的化学放射線療法 : NOBEL 試験**  
 渡辺 晃誠 (北里大学医学部 消化器内科学)

MO38-6 **The Role of Immunotherapy for Real-World Patients with HER2-negative Advanced Gastric Cancer between 2011-2023**  
 Keitaro Shimozaki (Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research)  
**HER2陰性切除不能進行・再発胃癌における免疫チェックポイント阻害剤の登場と治療成績:2011-2023における949例の検討**  
 下崎 啓太郎 (がん研究会有明病院消化器化学療法科)

15:10-16:10 Mini Oral Session 39

**MO39** Gastrointestinal Cancer 5 (Esophageal Cancer 2) E  
 消化管 5 (食道 2)

Chairs : Hironaga Satake (Department of Medical Oncology, Kochi Medical School)  
 Mitsuhiro Furuta (Department of Gastroenterology, Kanagawa Cancer Center)  
 司会 : 佐竹 悠良 (高知大学医学部腫瘍内科学講座)  
 古田 光寛 (神奈川県立がんセンター)

MO39-1 **Association between adjuvant UFT/LV efficacy and proton pump inhibitors in patients with stage II-III colorectal cancer**  
 Kaori Ito (Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine)  
**Stage II-III 結腸直腸癌患者における術後補助化学療法としてのUFT/LV療法の有効性とプロトンポンプ阻害薬との関連性**  
 伊藤 佳織 (藤田医科大学医学部薬物治療情報学)

MO39-2 **Risk factors for febrile neutropenia in patients with esophageal cancer: A supplementary analysis of JCOG1109**  
 Go Ikeda (Department of Gastroenterology, Nippon Medical School Graduate School of Medicine)  
**食道がん術前化学療法における発熱性好中球減少症のリスク因子解析 :JCOG1109の副次的解析**  
 池田 剛 (日本医科大学 消化器内科学)



- 
- MO39-3 **The safety and efficacy of induction DCF plus Nivo in patients with unresectable locally advanced esophageal carcinoma**  
Momoko Sano (Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital)  
**切除不能局所進行食道扁平上皮癌に対する導入 DCF+ ニボルマブ療法の安全性と短期的有効性**  
佐野 桃子 (国立がん研究センター中央病院 頭頸部・食道内科)
- 
- MO39-4 **Equivalent prognosis with pTx pN0 to pCR (pT0 pN0) in patients with localized advanced esophageal cancer after NAC DCF**  
Takashi Chinen (Department of Clinical Oncology, Jichi Medical University)  
**術前 DCF 後の限局性進行食道癌患者における ypCR(ypT0N0) と ypTxN0 の予後は同等である**  
知念 崇 (自治医科大学附属病院)
- 
- MO39-5 **演題取下**
- 
- MO39-6 **An observational study of geriatric assessment tools for elderly patients with resectable thoracic esophageal cancer**  
Kai Tsugaru (Department of Gastroenterology and Hepatology, Division of Internal Medicine, Keio University School of Medicine.)  
**高齢切除可能胸部食道癌患者における高齢者機能評価の有用性の多施設前向き観察研究**  
津軽 開 (慶應義塾大学医学部 内科学教室 (消化器))
-

## 第7会場 (神戸国際会議場 B1階 / 1階 メインホール)

8:30-10:00 Symposium 26 / シンポジウム 26

**SY26** "Focused"/"Spotlighted" Early Phase 1 Oncology Drug Development 2025  
がん新薬早期開発 2025 "Focused"/"Spotlighted" Early Phase Drug Development



Chairs : Yasutoshi Kuboki (Department of Experimental Therapeutics, National Cancer Center Hospital East)  
Toshio Shimizu (Department of New Experimental Therapeutics, International Cancer New Drug Development Center, Kansai Medical University Hospital/NEXT Oncology KMU JAPAN/NEXT Oncology, TX USA)  
司会 : 久保木 恭利 (国立がん研究センター東病院 先端医療科)  
清水 俊雄 (関西医科大学附属病院 新薬開発科・国際がん新薬開発センター /NEXT Oncology KMU JAPAN/NEXT Oncology, TX USA)

**SY26-1** Current situation and future prospects/issues of newly developed drugs (general discussion)

Shigehisa Kitano (The Cancer Institute Hospital of JFCR)

**新規開発薬剤の現状と今後の展望・課題 (総論)**

北野 滋久 (がん研究会有明病院)

**SY26-2** Current status and prospects of Tissue Agnostic Drug Development in Oncology

Megumi Ishiguro (Health Science Research & Development Center (HeRD), Institute of Science Tokyo)

**がん種横断的な医薬品開発の現状と今後の展望**

石黒 めぐみ (東京科学大学病院 ヘルスサイエンス R&D センター)

**SY26-3** Diversity in drug development

Takako Nakajima (Kyoto University Graduate School of Medicine)

**新薬開発における多様性**

中島 貴子 (京都大学大学院医学研究科 早期医療開発学)

**SY26-4** Japan's perspective in early development of anticancer drugs

Noboru Yamamoto (National Cancer Center Hospital)

**抗悪性腫瘍薬早期開発において日本のあるべき姿**

山本 昇 (国立がん研究センター中央病院)

10:10-11:40 Symposium 27 / シンポジウム 27

**SY27** Current state and future direction of immunotherapies in malignant lymphoma and multiple myeloma  
リンパ腫・骨髄腫に対する新たな免疫治療



Chairs : Kentaro Fukushima (Department of Hematology and Oncology, Osaka University Graduate School of Medicine)

Wee-Joo Chng (National University of Singapore)

司会 : 福島 健太郎 (大阪大学大学院医学系研究科 血液・腫瘍内科学)

Wee-Joo Chng (National University of Singapore)

**SY27-1** Bipefic Antibodies in Treatment of B-cell Lymphoma

Grzegorz Stanislaw Nowakowski (Mayo Clinic)

**SY27-2** CAR T-cell therapy for aggressive B-cell lymphomas in earlier line setting

Shinichi Makita (Department of Hematology, National Cancer Center Hospital)

**B細胞リンパ腫に対する早期治療ラインにおける CAR-T細胞療法**

蒔田 真一 (国立がん研究センター中央病院 血液腫瘍科)

- SY27-3 **Facilitating CAR-T cell therapy in the treatment of lymphoma and myeloma: effective operation of cell therapy**  
 Kentaro Fukushima (Dept. of Hematology and Oncology, Osaka University Graduate School of Medicine)  
**リンパ腫および骨髄腫治療における CAR-T 細胞療法を円滑に行うために：細胞療法の効果的な運用**  
 福島 健太郎 (大阪大学大学院医学系研究科 血液・腫瘍内科学)
- 
- SY27-4 **Development of immunotherapies to better control multiple myeloma: how to maximize their efficacy**  
 Takeshi Harada (Department of Hematology, Endocrinology and Metabolism, Tokushima Graduate School of Biomedical Sciences)  
**多発性骨髄腫に対する免疫療法の開発とその治療効果の最大化への課題**  
 原田 武志 (徳島大学大学院 血液・内分泌代謝内科学分野)
- 
- 14:00-16:00 **Joint Symposium 8 (JSPM / JSMO) / 合同シンポジウム 8 (日本緩和医療学会 / 日本臨床腫瘍学会)**
- 
- JS8** **Using Digital Technology in Supportive and Palliative Care for Cancer**  
**デジタル技術ががんの支持緩和医療に活かす**
- Chairs : Eriko Satomi (Department of Palliative Medicine, National Cancer Center Hospital)  
 Harue Arai (Osaka University Graduate School of Medicine)  
 司会 : 里見 絵理子 (国立がん研究センター中央病院 緩和医療科)  
 荒尾 晴恵 (大阪大学大学院 医学系研究科)
- 
- JS8-1** **Effective and efficient decision-making support for patients with advanced cancer using digital technology**  
**Encore**  
 Maiko Fujimori (National Cancer Center)  
**進行がん患者に対するデジタル技術を活用した効果的かつ効率的な意思決定支援**  
 藤森 麻衣子 (国立がん研究センター)
- 
- JS8-2** **Applying Decentralized Clinical Trials in the Supportive and Palliative Care**  
 Tatsuo Akechi (Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences)  
**デジタル技術をサポート緩和領域の臨床試験に応用する - 分散型臨床試験の経験から**  
 明智 龍男 (名古屋市立大学大学院医学研究科)
- 
- JS8-3** **Digital technology to support treatment and care for adolescent and young adult (AYA) patients with cancer**  
 Yuki Kojima (National Cancer Center Hospital)  
**AYA 世代がん患者の治療と療養を支えるデジタル技術**  
 小島 勇貴 (国立がん研究センター中央病院)
- 
- JS8-4** **AI Development in Cancer Palliative Care**  
 Masanori Mori (Seirei Mikatahara General Hospital)  
**がん緩和ケアにおける AI 開発**  
 森 雅紀 (聖隷三方原病院)
- 
- JS8-5** **Application of virtual reality (VR) in supportive and palliative care**  
 Kazuyuki Niki (The University of Osaka Graduate School of Pharmaceutical Sciences)  
**支持緩和療法におけるバーチャルリアリティ (VR) の活用**  
 仁木 一順 (大阪大学大学院薬学研究科)

## 第8会場 (神戸国際会議場 3階 国際会議室)

8:30-10:00 Symposium 28 / シンポジウム 28

**SY28** Current updates to learn about clinical trial modernization  
いま学ばべき臨床試験の適正化・効率化に向けた最新知見



Chairs : Hideharu Yamamoto (Chugai Pharmaceutical Co., Ltd.)  
Kenichi Nakamura (Department of International Clinical Development, National Cancer Center Hospital)

司会 : 山本 英晴 (中外製薬株式会社)  
中村 健一 (国立がん研究センター中央病院 国際開発部門)

### SY28-1 Summarizing Treatment Effects on Survival Time: Issues with Traditional Hazard Ratios and New Approaches

Hajime Uno (Dana-Farber Cancer Institute)

**生存時間における治療効果の要約: 伝統的ハザード比の問題点と新しいアプローチ**  
宇野 一 (Dana-Farber Cancer Institute)

### SY28-2 Newer statistical designs for non-inferiority trials

Shogo Nomura (The University of Tokyo, Graduate School of Medicine)

**新しい非劣性デザインのすすめ**  
野村 尚吾 (東京大学大学院 医学系研究科)

### SY28-3 Opportunities and Challenges of Complex Innovative Trial Designs

Martin Posch (Medical University of Vienna)

### SY28-4 The impact of adaptive design on clinical trials

Hideki Suganami (Kowa co., ltd.)

**adaptive design がもたらす臨床試験への影響**  
菅波 秀規 (興和株式会社)

10:10-11:40 Symposium 29 / シンポジウム 29

**SY29** Rare cancers with promising drugs in the future  
希少がんに対する今後有望となる薬剤



Chairs : Takafumi Koyama (Department of Experimental Therapeutics, National Cancer Center Hospital)  
Akihiro Nishiyama (Department of Medical Oncology, Kanazawa University Hospital)

司会 : 小山 隆文 (国立がん研究センター中央病院 先端医療科)  
西山 明宏 (金沢大学附属病院 腫瘍内科)

### SY29-1 The current status and future of EZH2 inhibitors in epithelioid sarcoma or other rare solid tumors

Tatsunori Shimoi (Department of Medical Oncology, National Cancer Center Hospital)

**上皮肉腫やその他希少がんにおける EZH2 阻害薬の現状と未来**  
下井 辰徳 (国立がん研究センター中央病院 腫瘍内科)

### SY29-2 Current status of PDGFR inhibitors in GIST

Toshihiko Doi (National Cancer Center Hospital East)

**GIST における PDGFR 阻害薬の現状**  
土井 俊彦 (国立がん研究センター東病院)

SY29-3 **Development of ALK inhibitors for ALK fusion gene-positive solid tumors, including inflammatory myofibroblast tumors (IMT)**

Toshiki Masuishi (Department of Clinical Oncology, Aichi Cancer Center Hospital)

**炎症性筋線維芽細胞腫瘍 (IMT) を含む ALK 融合遺伝子陽性固形腫瘍に対する ALK 阻害薬の開発**

舛石 俊樹 (愛知県がんセンター 薬物療法部)

SY29-4 **Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma -Brigimadlin (BI-907827)-**

Akira Kawai (Department of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital)

**脱分化型脂肪肉腫に対する MDM2-p53 パスウェイ阻害剤 -Brigimadlin (BI-907827)-**

川井 章 (国立がん研究センター中央病院 骨軟部腫瘍・リハビリテーション科)

SY29-5 **Promising Future Treatments for Brain Tumors: Precision Medicine and Gene Therapy**

Kazuhiko Kurozumi (Department of Neurosurgery, Hamamatsu University School of Medicine)

**脳腫瘍に対する今後有望となる治療 - Precision Medicine と遺伝子治療**

黒住 和彦 (浜松医科大学 脳神経外科)

14:00-15:30 Symposium 30 / シンポジウム 30

**SY30** Future outlook on MRD testing in peri-operative clinical trials  
MRD 検査が切り拓く周術期試験デザインの近未来



Chairs : Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital)

Shogo Nomura (Graduate School of Medicine, The University of Tokyo)

司会 : 堀之内 秀仁 (国立がん研究センター中央病院 呼吸器内科)

野村 尚吾 (東京大学大学院 医学系研究科)

SY30-1 **SCRUM-MONSTAR & CIRCULATE-Japan platform to accelerate precision oncology innovations; achievement and perspective**

Takayuki Yoshino (National Cancer Center Hospital East)

**固形癌におけるがんゲノム医療の現状と展望 - SCRUM & CIRCULATE-Japan の成果から紐解く**

吉野 孝之 (国立がん研究センター東病院)

SY30-2 **Perspectives on New Clinical Trial Endpoints Using Molecular Residual Disease Testing**

Hideaki Bando (National Cancer Center Hospital East)

**Molecular Residual Disease 検査の用いた新しい臨床試験エンドポイントの展望**

坂東 英明 (国立がん研究センター東病院)

SY30-3 **Key points for evaluation in clinical trials using MRD and future challenges**

Akinari Tsukada (Pharmaceuticals and Medical Devices Agency)

**MRD を用いた臨床試験の評価のポイントと今後の課題**

塚田 晃成 (独立行政法人 医薬品医療機器総合機構)

SY30-4 **Issues and perspectives on MRD-based clinical development in thoracic oncology**

Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital)

**肺がん臨床試験における課題と今後**

堀之内 秀仁 (国立がん研究センター中央病院 呼吸器内科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

15:30-16:30 Mini Oral Session 40

**MO40** Clinical Trial Facilitation Program 2  
臨床試験推進プログラム 2



Chairs : Tomohiro Terada (Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital)  
Natsuko Okita (Clinical Research Support Office, National Cancer Center Hospital)  
司会 : 寺田 智祐 (京都大学医学部附属病院)  
沖田 南都子 (国立がん研究センター中央病院臨床研究支援部門)

**MO40-1** Impact of the accelerated approval for cancer drugs of the U.S. FDA on the drug evaluation process by the Japan PMDA

Yasutsuna Sasaki (Rakuwakai-Otowa Hospital)

米国医 FDA による迅速承認制度が、わが国の PMDA による新規医薬品の審査・承認に及ぼす影響

佐々木 康綱 (洛和会音羽病院)

**MO40-2** Regulatory landscape of CAR-T cell and bi-specific antibody products for lymphoid neoplasm in the US, EU, and Japan

Encore

Kensuke Matsuda (Pharmaceuticals and Medical Devices Agency)

CAR-T 細胞及び二重特異性抗体製剤の米国、欧州、日本における薬事承認

松田 健佑 (医薬品医療機器総合機構)

**MO40-3** Efforts aimed at achieving optimal transportation for samples in clinical trials

Hiroyuki Kodama (Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University)

臨床試験での検体輸送において最適な輸送環境を目指した取り組み

児玉 紘幸 (大阪医科薬科大学 化学療法センター)

**MO40-4** Comparison of Dose Rounding and Drug Vial Optimization for Reducing Anticancer Drug Waste

Tomohiko Harada (Department of pharmacy)

Dose Rounding と Drug Vial Optimization の抗がん薬における残薬削減効果の比較

原田 知彦 (神奈川県立足柄上病院)

**MO40-5** Public Assistance and Survival Equality in Patients with EGFR Mutation-Positive Lung Cancer

Kiyoaki Uryu (Medical Oncology, Yao Tokushukai General Hospital)

EGFR 遺伝子変異陽性肺癌患者における公的扶助と生存の平等性

瓜生 恭章 (八尾徳洲会総合病院)

**MO40-6** CLARITY-Gastric 01: a randomized Phase 3 study of AZD0901 in 2L+ advanced gastric/gastroesophageal junction cancers

Encore

Nozomu Machida (Department of Gastroenterology, Kanagawa Cancer Center)

進行 / 転移性胃又は胃食道接合部腺癌を有する二次治療以降の患者における AZD0901 の第 III 相ランダム化試験 (CLARITY-Gastric 01)

町田 望 (神奈川県立がんセンター 消化器内科)

## 第9会場 (神戸国際会議場 4階 会議室 401 + 402)

8:30-9:30 Mini Oral Session 41

**MO41** Translational Research / Clinical Pharmacology 2  
TR・臨床薬理 2

**E**

Chairs : Kazuo Kasahara (Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School)  
Kazuhiro Kishi (Department of Gastroenterology, Tokushima Red Cross Hospital)  
司会 : 笠原 寿郎 (日本医科大学呼吸器内科学)  
岸 和弘 (徳島赤十字病院消化器内科)

**MO41-1** **Multomics clustering of cutaneous melanoma patients to reveal survival trends based on tumor immune evasion features**

**Encore** Adeliya Leleytner (BostonGene, Corp.)

**MO41-2** **Pan-Cancer Analysis of POTE Ankyrin Domain Family Member F's Prognostic Significance: From Genome to Transcriptome**

Amir Avan (School of biomedical sciences, Queensland University of Technology)

**MO41-3** **Integrating RNA Modifications and Spatial Proteomics with Machine Learning to Predict Immune Escape in Solid Tumor**

Sahnaz V Putri (Health Management Laboratory, International University Semen Indonesia)

**MO41-4** **Unraveling sarcomatoid features in clear cell renal cell carcinoma with RNA-seq**

**Encore** Kirill Kryukov (BostonGene, Corp.)

**MO41-5** **Mucosal vaccine mediates HPV-positive OPSCC regression by the activation of CD69+ tissue-resident memory CD8+ T cells**

Ke Qiu (West China Hospital, Sichuan University)

**MO41-6** **Identification of URST8 as a novel biomarker and therapeutic target for lung cancer**  
Atsushi Takano (The institute of Medical Science, The University of Tokyo, Center for antibody and vaccine)

**肺がんの新規バイオマーカー、治療標的分子 URST8 の同定**

高野 淳 (東京大学医科学研究所抗体ワクチンセンター)

9:30-10:30 Mini Oral Session 42

**MO42** Translational Research / Clinical Pharmacology 3 (Basic Research)  
TR・臨床薬理 3 (基礎)

**E**

Chairs : Hideki Maeda (Regulatory Science, Meiji Pharmaceutical University)  
Takahiro Kogawa (Cancer Institute Hospital of JFCR)  
司会 : 前田 英紀 (明治薬科大学)  
古川 孝広 (がん研有明病院)

**MO42-1** **Characterization of URST4 as a new precise molecular biomarker and therapeutic target for breast cancer**

Hoa T Nguyen (Shiga University of Medical Science)

**MO42-2** **The Impact of Complement C3 on Diverse Cell Types in Immune Checkpoint Blockade Therapy**

Yuki Miyai (Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital)

**免疫チェックポイント阻害療法における細胞腫別補体 C3 の役割**

宮井 雄基 (名古屋大学医学部附属病院 化学療法部)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

MO42-3 **Efficacy of Combined Anti-PD-1 and Anti-CTLA-4 Antibodies Based on the Intracranial Tumor Microenvironment**  
 Toshifumi Ninomiya (Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)

**腫瘍微小環境の解析に基づいた転移性脳腫瘍に対する抗 PD-1 抗体と抗 CTLA-4 抗体の併用療法の検証**  
 二宮 利文 (岡山大学学術研究院医歯薬学域 腫瘍微小環境学分野)

MO42-4 **Orthotopic and subcutaneous murine models of HPV-positive OPC: distinct mechanisms of suppressive tumor microenvironment**  
 Minzi Mao (West China Hospital of Sichuan University)

MO42-5 **DKK1 Drives Ferroptosis in Immature Neutrophils and Shapes an Immunosuppressive Tumor Microenvironment**  
 Shiji Ren (Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.)

MO42-6 **mRNA-LNP vaccination orchestrates systemic immunity to control human papillomavirus-positive oropharyngeal carcinoma**  
 Jianjun Ren (West China Hospital, Sichuan University)

10:30-11:30 Mini Oral Session 43

**MO43** Translational Research / Clinical Pharmacology 4  
 (Molecular Diagnostics / Genomic Medicine / Companion Diagnostics)  
 TR・臨床薬理 4 (分子・遺伝子診断・コンパニオン診断) **E**

Chairs : Mizugaki Hidenori (Department of Respiratory Medicine, NHO Hokkaido Cancer Center)  
 Kaoru Tanaka (Department of Medical oncology, Kindai University Faculty of Medicine.)  
 司会 : 水柿 秀紀 (北海道がんセンター)  
 田中 薫 (近畿大学医学部内科学教室腫瘍内科部門)

MO43-1 **Development of a Novel Machine Learning-Based Model for Enhanced Pathogenicity Prediction of Missense Variants**  
 Haruko Nakagawa (Department of Functional Genome Informatics, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo)

**ミスセンス変異の病原性予測のための in silico 機能予測とゲノム情報を統合した新しい機械学習モデルの開発**  
 中川 晴子 (東京科学大学 難治疾患研究所 ゲノム機能情報分野)

MO43-2 **Clinical Characteristics and Chemo-effect in Germline TP53 Pathogenic Variant Cases Identified by Cancer Genomic Testing**  
 Yosuke Saito (Gastroenterology)

**がん遺伝子パネル検査で同定された生殖細胞系列 TP53 病的バリエーション症例の臨床的特徴および化学療法の効果**  
 齋藤 陽介 (山形市立病院済生館)

MO43-3 **A reality of cancer genomic medicine in Japan looking from C-CAT registered data**  
 Naoto Koashi (C-CAT, National Cancer Center)

**C-CAT 登録データに見る日本のがんゲノム医療の実情**  
 小芦 尚人 (国立がん研究センター がんゲノム情報管理センター)

MO43-4 **Blood re-sampling improves detection of actionable gene alterations by liquid biopsy**  
 Taku Murakami (Guardant Health Japan)



MO43-5 **Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: a retrospective cohort study**

Tomoyuki Iwasaki (Department of Medical Oncology, Tohoku University Hospital)

**NRF2-KEAP1 システム遺伝子変異のがん種特異性と予後 :C-CAT データベースを用いた解析**  
岩崎 智行 (東北大学病院腫瘍内科)

MO43-6 **Initial Biomarker Selection Impacts Clinical Outcomes in Advanced Non-Small Cell Lung Cancer: A Cohort Study**

Masaki Ishida (Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajii-cho, Kamigyo-ku, Kyoto, Japan)

**遺伝子診断法の差異による進行・再発非小細胞肺癌の臨床転帰の検討 :多施設共同後方視的観察研究**

石田 真樹 (京都府立医科大学附属病院)

14:00-15:00 Mini Oral Session 44

**MO44** Hematologic Malignancies 3 (Lymphoma 1)  
血液 3 (リンパ腫 1)

**E**

Chairs : Yoshihiro Yakushijin (Department of Clinical Oncology, Ehime University Graduate School of Medicine)

Tsutomu Sato (Department of Hematology, Faculty of Medicine, Academic Assembly, University of Toyama)

司会 : 薬師神 芳洋 (愛媛大学医学部臨床腫瘍学)  
佐藤 勉 (富山大学学術研究部医学系血液内科)

MO44-1 **Zanubrutinib + Obinutuzumab vs Last Prior Treatment in R/R Follicular Lymphoma: Growth Modulation Index From ROSEWOOD**

Minoru Kanaya (Blood Disorders Center, Aikku Hospital)

**再発難治性濾胞性リンパ腫を対象とした ROSEWOOD study における Growth Modulation Index を用いたザヌブルチニブ + オビヌツズマブ療法と前治療との有効性の比較**  
金谷 穰 (愛育病院)

MO44-2 **Odronextamab in patients with relapsed/refractory follicular lymphoma: Primary analysis of the Phase 2 ELM-2 study**

Tae Min Kim (Seoul National University Hospital, Seoul, South Korea)

MO44-3 **Odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma: Phase 2 ELM-2 study primary analysis**

Won Seog Kim (Samsung Medical Center, Center for Hematologic Malignancy, Seoul, South Korea)

MO44-4 **3-Year Update From EPCORE NHL-1: Epcoritamab Leads to Deep and Durable Responses in R/R LBCL**

Yasmin H Karimi (University of Michigan Division of Hematology/Oncology)

MO44-5 **EPCORE DLBCL-3: Fixed-Duration Epcoritamab in Older, Anthracycline-Ineligible Patients With Previously Untreated LBCL**

Takahiro Kumode (Department of Hematology and Rheumatology, Kindai University)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

**MO44-6 Retrospective observational study of ibrutinib in Japanese patients with CLL (Orbit study)**

**Encore**  
 Shuichi Ohta (Department of Hematology, Sapporo Hokuyu Hospital)  
**日常診療においてイブルチニブ治療を受けた日本人慢性リンパ性白血病患者を対象とした後ろ向き観察研究**  
 太田 秀一 (札幌北楡病院 血液内科)

15:10-16:00 Mini Oral Session 45

**MO45 Hematologic Malignancies 4 (Lymphoma 2)** **E**  
 血液 4 (リンパ腫 2)

Chairs : Kazuya Shimoda (Department of hematology, diabetes, and endocrinology, University of Miyazaki)  
 Kenji Ishitsuka (Department of Hematology and Rheumatology, Kagoshima University)  
 司会 : 下田 和哉 (宮崎大学 血液・糖尿病・内分泌内科)  
 石塚 賢治 (鹿児島大学医歯学総合研究科 血液・膠原病内科学分野)

**MO45-1 Patient-Reported Outcomes in Patients With Relapsed or Refractory Follicular Lymphoma Treated With Epcoritamab**

**Encore**  
 Wojciech Jurczak (MSC National Research Institute of Oncology)

**MO45-2 Ibrutinib Plus Venetoclax in Patients With Mantle Cell lymphoma (MCL) and TP53 mutations in the SYMPATICO Study**

**Encore**  
 Marek Trnety (General University Hospital in Prague)

**MO45-3 演題取下**

**MO45-4 Epcoritamab in Japanese Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma: 3-Year EPCORE NHL-3 Data**

Koji Izutsu (Department of Hematology, National Cancer Center Hospital)

**MO45-5 Deep, Durable Responses With Epcoritamab in Relapsed/Refractory Follicular Lymphoma (R/R FL): 3-Year EPCORE NHL-3 Data**

Koji Izutsu (Department of Hematology, National Cancer Center Hospital)

## 第10会場 (神戸国際会議場 5階 会議室 501)

8:50-9:40 Mini Oral Session 46

**MO46** Lung Cancer / Thoracic Cancer 5 (Non-Small Cell Lung Cancer 1 (Immunotherapy 1))  
呼吸器 5 (非小細胞肺癌 1 (免疫療法 1))

**E**

Chairs : Hiroshi Nokihara (Department of Respiratory Medicine, Center Hospital of the National Center for Global Health and Medicine)  
Kyoichi Kaira (Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University)

司会 : 軒原 浩 (国立国際医療研究センター病院)  
解良 恭一 (埼玉医科大学 国際医療センター 呼吸器内科)

**MO46-1** GALAXIES Lung-201 Interim Analysis: Belrestotug Plus Dostarlimab in Patients With PD-L1 High Non-Small Cell Lung Cancer

**Encore**

Hidetoshi Hayashi (Department of Medical Oncology, Kindai University Faculty of Medicine)  
林 秀敏 (近畿大学医学部)

**MO46-2** The Impact of Gut Microbiome on the Efficacy of Ipilimumab plus Nivolumab in Patients with Advanced NSCLC

Yuki Katayama (Kyoto Prefectural University of Medicine)

進行非小細胞肺癌におけるイピリムマブ・ニボルマブ併用療法の有効性に対する腸内細菌叢の影響

片山 勇輝 (京都府立医科大学附属病院)

**MO46-3** Microbiome Impact of PPI and Antibiotics on ABCP Therapy in Advanced Non-SQ NSCLC: A Phase II Study (K-TAIL-201)

Takahiro Yoshizawa (Division of Respiratory Medicine, Toho University School of Medicine)

進行非扁平上皮非小細胞肺癌における ABCP 療法への PPI と抗生物質の影響と腸内細菌叢の探索: 第 II 相試験 (K-TAIL-201)

吉澤 孝浩 (東邦大学医学部内科学講座呼吸器内科学分野)

**MO46-4** Phase II study of multidisciplinary therapy for patients with oligometastatic NSCLC (WJOG11118L): Feasibility analysis

**Encore**

Kentaro Tanaka (Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University)

オリゴ転移を伴う非小細胞肺癌に対する集学的治療の第 II 相試験 (WJOG11118L): 忍容性解析

田中 謙太郎 (九州大学病院 呼吸器内科)

**MO46-5** Real-World Effectiveness of Second-Line Therapies in Elderly Non-Small Cell Lung Cancer: NEJ057

Ou Yamaguchi (Saitama Medical University International Medical Center)

高齢者非小細胞肺癌における二次治療の有効性について: NEJ057 試験サブセット解析  
山口 央 (埼玉医科大学国際医療センター)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

**MO47** Lung Cancer / Thoracic Cancer 6 (Non-Small Cell Lung Cancer 2 (Immunotherapy 2))  
呼吸器 6 (非小細胞肺癌 2 (免疫療法 2))

Chairs : Yasuhiko Nishioka (Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University)  
Nobuhiko Seki (Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine)

司会 : 西岡 安彦 (徳島大学大学院医歯薬学研究部 呼吸器・膠原病内科学分野)  
関 順彦 (帝京大学医学部内科学講座腫瘍内科)

**MO47-1** Early administration of immune checkpoint inhibitors ± chemotherapy affects efficacy in patients with advanced NSCLC

Yuko Oya (Department of Respiratory Medicine and Clinical Allergy, Fujita Health University)

**進行肺がん患者における免疫チェックポイント阻害薬±化学療法の投与時間帯が治療効果に及ぼす影響**

大矢 由子 (藤田医科大学 医学部 呼吸器内科学)

**MO47-2** Efficacy of Chemotherapy with or without Immunotherapy in Elderly NSCLC Patients with Low PD-L1 Expression

Hayato Kawachi (Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine)

**PD-L1 TPS 1-49% の高齢者非小細胞肺癌における複合免疫療法の有効性: 多施設後ろ向き観察研究**

河内 勇人 (京都府立医科大学附属病院)

**MO47-3** Chemo-immunotherapy versus chemotherapy based on study eligibility criteria in advanced NSCLC with low PD-L1 expression

Naoki Furuya (Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine)

**PD-L1 低発現進行非小細胞肺癌における治験適格基準をふまえた複合免疫療法の検討**

古屋 直樹 (聖マリアンナ医科大学)

**MO47-4** History of antibiotic use in advanced non-small cell lung cancer with PD-L1 low expression

Satoshi Watanabe (Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences)

**PD-L1 低発現進行非小細胞肺癌における抗菌薬投与歴の影響**

渡部 聡 (新潟大学医歯学総合病院)

**MO47-5** An increased relative eosinophil count as a predictive dynamic biomarker in NSCLC patients treated with ICIs

Eiji Takeuchi (Department of Respiratory Medicine, National Hospital Organization Kochi Hospital)

**好酸球増加は非小細胞肺癌患者の免疫チェックポイント阻害薬治療効果予測バイオマーカー**

竹内 栄治 (NHO 高知病院 呼吸器内科)

**MO47-6** A Phase II study of cisplatin and gemcitabine plus necitumumab after immunotherapy: WJOG14120L NESSIE study**Encore**

Nobuhisa Ishikawa (Hiroshima Prefectural Hospital)

**免疫化学療法後に再燃した進行・再発の肺扁平上皮癌患者を対象としたシスプラチン、ゲムシタピン、ネシツムマブ併用療法の多施設共同第 II 相試験: WJOG14120L NESSIE study**

石川 暢久 (県立広島病院)

**MO48** Lung Cancer / Thoracic Cancer 7 (Non-Small Cell Lung Cancer 3 (Perioperative Treatment, Locally Advanced))  
呼吸器 7 (非小細胞肺癌 3 (周術期、局所進行))

E

Chairs : Shunichi Sugawara (Department of Pulmonary Medicine, Sendai Kousei Hospital)  
Masahiro Seike (Department of Pulmonary Medicine and Oncology, Graduate School of Medicine,  
Nippon Medical School)

司会 : 菅原 俊一 (仙台厚生病院)  
清家 正博 (日本医科大学大学院医学研究科呼吸器内科学分野)

**MO48-1** **A Multicenter Phase II Trial of Erlotinib Induction Followed by Surgery in EGFR  
Encore mutated cN2 Non-Small Cell Lung Cancer**

Seiji Niho (Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical  
University)

**EGFR 変異陽性 cN2 非小細胞肺癌に対するエルロチニブ導入療法後の手術の多施設共同第 II  
相試験**

仁保 誠治 (獨協医科大学)

**MO48-2** **Perioperative durvalumab(D) for resectable NSCLC (R-NSCLC): updated outcomes  
Encore from the phase 3 AEGEAN trial**

Tetsuya Mitsudomi (President, Faculty of Medicine, Izumi City General Hospital and Kindai  
University)

**切除可能な非小細胞肺癌の周術期治療としてのデュルバルマブ : 第 3 相 AEGEAN 試験の  
最新結果**

光富 徹哉 (Izumi City General Hospital and Kindai University)

**MO48-3** **Neoadjuvant nivolumab + chemotherapy in resectable NSCLC: 4-year update and  
Encore Asian subpopulation data from CheckMate 816**

Tetsuya Mitsudomi (Kindai University Faculty of Medicine)

**切除可能非小細胞肺癌におけるニボルマブと化学療法の併用術前補助療法 : CheckMate  
816 4-year update 及びアジア人サブ集団解析**

光富 徹哉 (近畿大学医学部)

**MO48-4** **Triumph Over Progression: Surgical Outcomes in NSCLC Patients with Progressive  
Disease Post-Neoadjuvant Immunotherapy**

Long Jiang (Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine)

**MO48-5** **Assessing Surgical Intervention Following Neoadjuvant Immuno-Chemotherapy in  
T3-4N2 Stage IIIB NSCLC Treatment**

Long Jiang (Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine)

**MO48-6** **A randomized phase III study of chemoradiotherapy in elderly patients with  
Encore unresectable locally advanced NSCLC: JCOG1914**

Yuki Shinno (National Cancer Center Hospital)

**高齢者切除不能局所進行非小細胞肺癌に対する化学放射線療法のランダム化第 III 相試  
験 : JCOG1914**

新野 祐樹 (国立がん研究センター中央病院・呼吸器内科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

14:00-15:00 Mini Oral Session 49

**MO49** Lung Cancer / Thoracic Cancer 8 (Non-Small Cell Lung Cancer 4 (TKI 1))  
呼吸器 8 (非小細胞肺癌 4 (TKI 1))



Chairs : Koichi Takayama (Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine)  
Masayuki Takeda (Department of Cancer Genomics and Medical Oncology, Nara Medical University)

司会 : 高山 浩一 (京都府立医科大学大学院医学研究科内科学呼吸器内科分野)  
武田 真幸 (奈良県立医科大学 がんゲノム・腫瘍内科)

**MO49-1** Osimertinib and Other EGFR-TKIs on Overall Survival in Untreated Advanced EGFR-Mutated NSCLC in Japan:TREAD 01 Update

Makoto Hibino (Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital)

未治療進行 EGFR 変異非小細胞肺癌に対するオシメルチニブおよび他 EGFR-TKI 初回治療の全生存期間への影響 :TREAD プロジェクト 01 の最新データ

日比野 真 (湘南藤沢徳洲会病院)

**MO49-2** Biomarker analysis of plasma samples in YAMATO study: assessing switching strategy of osimertinib following afatinib

**Encore**

Hidetoshi Itani (Department of Respiratory Medicine)

YAMATO 試験 (アファチニブとオシメルチニブの切り替え療法のランダム化試験): 血漿バイオマーカーの探索的解析 (TORG1939/WJOG12919L)

井谷 英敏 (伊勢赤十字病院)

**MO49-3** Ramucirumab + erlotinib for EGFR L858R mutated NSCLC (REAL-SPEED): analysis of efficacy and adverse event management

Yuki Takeyasu (Department of Thoracic Oncology, Kansai Medical University)

EGFR L858R 陽性肺癌に対するラムシルマブ + エルロチニブ療法 (REAL-SPEED 試験): 有効性と有害事象対策に関する解析

竹安 優貴 (関西医科大学呼吸器腫瘍科)

**MO49-4** A Phase 2 study of osimertinib in NSCLC patients with CNS metastases after treatment with 1st or 2nd-generation EGFR-TKI

Masayuki Takeda (Department of Medical Oncology, Kindai University Faculty of Medicine)

第 1・2 世代 EGFR-TKI 治療後、脳転移単独増悪を認めた NSCLC に対するオシメルチニブの第 2 相試験 (医師主導試験)

武田 真幸 (近畿大学医学部 腫瘍内科)

**MO49-5** Efficacy of osimertinib in NSCLC patients with uncommon EGFR exon 19 deletion using nationwide genomic database (C-CAT)

Kentaro Goshō (Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital)

稀な EGFR エクソン 19 欠失を有する非小細胞肺癌患者に対するオシメルチニブの有効性に関する C-CAT データベースを用いた検討

御所 健太郎 (がん・感染症センター 都立駒込病院 呼吸器内科)

**MO49-6** Phase II study of carboplatin, pemetrexed, bevacizumab and erlotinib in EGFR-mutated non-small-cell lung cancer (NEJ035)

Hiroshige Yoshioka (Kansai Medical University)

上皮成長因子受容体遺伝子変異陽性非扁平上皮非小細胞肺癌に対するエルロチニブとカルボプラチン、ペメトレキセド、ベバシズマブ併用療法の第 II 相試験 (NEJ035)

吉岡 弘鎮 (関西医科大学)

**MO50** Lung Cancer / Thoracic Cancer 9 (Non-Small Cell Lung Cancer 5 (TKI 2))  
呼吸器 9 (非小細胞肺癌 5 (TKI 2))

Chairs : Yasuhito Fujisaka (Medical Oncology, Osaka Medical and Pharmaceutical University)  
Kentaro Tanaka (Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University)

司会 : 藤阪 保仁 (大阪医科薬科大学医学部 内科学講座腫瘍内科学)  
田中 謙太郎 (鹿児島大学大学院医歯学総合研究科呼吸器内科学)

**MO50-1** A phase II study of cabozantinib in NSCLC harboring MET exon14 alterations resistance to tepotinib or capmatinib

Masayuki Takeda (Department of Cancer Genomics and Medical Oncology, Nara Medical University)

テポチニブまたはカプマチニブに獲得耐性を示した MET 遺伝子エクソン 14 変異陽性非小細胞肺癌患者に対するカボザンチニブを用いた非盲検第二相試験

武田 真幸 (奈良県立医科大学)

**MO50-2** Safety and Efficacy of BAY 2927088 In Patients with *HER2* -Mutant NSCLC: Expansion Cohort from the SOHO-01 Study

Koichi Goto (National Cancer Center Hospital East)

*HER2* 変異 NSCLC 患者における BAY 2927088 の安全性と有効性 :SOHO-01 試験の拡大コホート

後藤 功一 (国立がん研究センター東病院)

**MO50-3** Gumarontinib for NSCLC harboring MET exon 14 skipping (METex14) mutations: Updated Japanese subgroup of the GLORY study

Kazumi Nishino (Department of Thoracic Oncology, Osaka International Cancer Institute)

MET 遺伝子エクソン 14 スキッピング変異陽性の非小細胞肺癌に対するグマロンチニブ : GLORY 試験の日本人解析アップデート

西野 和美 (大阪国際がんセンター 呼吸器内科)

**MO50-4** Amivantamab Plus Lazertinib vs Osimertinib in 1L EGFR-mutant Advanced NSCLC: Longer Follow-up of MARIPOSA Study

Shun Lu (Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University)

**MO50-5** Mechanisms of Acquired Resistance to 1st-line treatment in Patients With EGFR-mutant Advanced NSCLC: MARIPOSA Study

Hidetoshi Hayashi (Department of Medical Oncology, Kindai University Faculty of Medicine)

Mechanisms of Acquired Resistance to 1st-line treatment in Patients With EGFR-mutant Advanced NSCLC: MARIPOSA Study

林 秀敏 (近畿大学医学部内科学腫瘍内科部門)

**MO50-6** Sotorasib long-term clinical outcomes in KRAS G12C-mutated advanced NSCLC: pooled analysis from the CodeBreak trials

Makoto Nishio (The Cancer Institute Hospital of Japanese Foundation for Cancer Research)

前治療歴を有する KRAS G12C 変異性進行非小細胞肺癌に対するソトラシブ長期投与による治療効果 (CodeBreak 試験プール解析)

Makoto Nishio (The Cancer Institute Hospital of Japanese Foundation for Cancer Research)

**MO50-7** A Prospective Comprehensive Genomic Profiling Study in Treatment Naïve Advanced Non-Small Cell Lung Cancer Patients

Pei Jye Voon (Hospital Umum Sarawak)

第 11 会場 (神戸国際会議場 5 階 会議室 502)

8:30-9:30 Mini Oral Session 51

MO51 Genitourinary Cancer 2 (Prostate Cancer, Urothelial Cancer -Clinical -)  
泌尿器 2 (前立腺癌・尿路上皮癌 臨床)

E

Chairs : Keita Uchino (Department of Medical Oncology, Toranomon Hospital)  
Chihiro Kondoh (Department of Medical Oncology, National Cancer Center Hospital East)  
司会 : 内野 慶太 (虎の門病院臨床腫瘍科)  
近藤 千紘 (国立がん研究センター東病院 腫瘍内科)

MO51-1 **The epidemiology, treatment and survival outcomes of prostate cancer: a cohort study in Taiwan**  
Chinghu Chung (Department of Medicine, Mackay Medical College)

MO51-2 **The analysis of active surveillance for elderly early-stage prostate cancer patients: From the PRIAS-JAPAN study**  
Takuma Kato (Department of Urology, Faculty of medicine, Kagawa University)  
**日本人高齢前立腺癌患者に対する監視療法の解析 -PRIAS-JAPAN study より -**  
加藤 琢磨 (香川大学医学部泌尿器科)

MO51-3 **Detection rate & impact on clinical management of 68Ga-PSMA-11 PET/CT for prostate cancer patients with undetectable PSA**  
**Encore**  
Mariko Nakayama (UCLA)

MO51-4 **Real-world analysis of avelumab first-line maintenance (1LM) for advanced urothelial carcinoma in Japan by start date**  
Hiroshi Kitamura (Department of Urology, Faculty of Medicine, University of Toyama)  
**進行性尿路上皮癌に対するアベルマブ維持療法: リアルワールドデータ解析**  
北村 寛 (富山大学 学術研究部医学系 腎泌尿器科学)

MO51-5 **Quality of Life in a Real-World Cohort of Patients with Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors**  
Takahito Negishi (NHO Kyushu Cancer Center)  
**免疫チェックポイント阻害薬治療を受けた進行尿路上皮癌患者における QOL の検討**  
根岸 孝仁 (九州がんセンター)

MO51-6 **FAN score predicts prognosis after platinum-based chemotherapy in patients with metastatic urothelial carcinoma**  
Yu Ishizuya (Department of Urology Graduate School of Medicine, Osaka University)  
**FAN スコアは転移性尿路上皮がん患者における白金製剤ベースの一次化学療法後の予後を予測する**  
石津谷 祐 (大阪大学大学院医学系研究科器官制御外科学講座 (泌尿器科学))



**MO52** Genitourinary Cancer 3 (Prostate Cancer, Urothelial Cancer, Basic Research, Other)  
泌尿器 3 (前立腺癌・尿路上皮癌 基礎・その他)**E**

Chairs : Ravindran Kanesvaran (National Cancer Centre Singapore)  
Taigo Kato (Department of Urology, Osaka University Graduate School of Medicine)  
司会 : Ravindran Kanesvaran (National Cancer Centre Singapore)  
加藤 大悟 (大阪大学大学院医学系研究科泌尿器科)

**MO52-1** Outcomes of metastatic hormone-sensitive prostate cancer in Asians with homologous recombinant repair gene mutations

Daniel Ang (Division of Medical Oncology, National Cancer Centre Singapore)

**MO52-2** Investigating the expression of long non-coding RNAs in Prostate cancer

Poornima Verma (sanjay gandhi post graduate institute of medical sciences)

**MO52-3** The miRNAs 203a/210-3p/5001-5p regulate the androgen/androgen receptor/YAP-induced migration in prostate cancer cells

Chieh Huo (Institute of Cellular and System Medicine, National Health Research Institutes)

**MO52-4** Expression of tumor-associated mucin 1 in bladder and upper urinary tract cancers

Chihiro Kondoh (Department of Medical Oncology, National Cancer Center Hospital East)

膀胱がんおよび上部尿路がんにおける tumor-associated mucin 1 発現

近藤 千紘 (国立がん研究センター東病院 腫瘍内科)

**MO52-5** To investigate the association between heavy metal and epigenetic modulation in Urothelial Bladder Cancer

Ganesh K Verma (ALL INDIA INSTITUTE OF MEDICAL SCIENCES RISHIKESH UTTARAKHAND 249203)

**MO52-6** Clinical Outcomes of First-line Chemotherapy in Urachal Adenocarcinoma Based on Pathological Characteristics

Toru Imai (Department of Medical Oncology, National Cancer Center Hospital)

尿管管がんの病理学的特徴に基づいた一次治療における臨床経過

今井 亨 (国立がん研究センター中央病院 腫瘍内科)

**MO53** Gastrointestinal Cancer 6 (Colorectal Cancer 1, Other Basic)  
消化管 6 (大腸 1・その他 基礎)**E**

Chairs : Tomohiro Nishina (Department of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center.)  
Shuichi Hironaka (Department of Medical Oncology)  
司会 : 仁科 智裕 (国立病院機構四国がんセンター 消化器内科)  
廣中 秀一 (杏林大学医学部腫瘍内科学)

**MO53-1** Phase II trial shows promise for new drug preventing oxaliplatin-induced neuropathy and hypersensitivity reactions

Atsushi Ishiguro (Medical Oncology, Teine Keijinkai Hospital)

術後補助化学療法として mFOLFOX6 療法を実施する大腸がん患者を対象とした化学療法誘発性末梢神経障害に対する PC-SOD の第 II 相プラセボ対照二重盲検比較試験

石黒 敦 (手稲溪仁会病院)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

MO53-2 **Exploiting metabolic reprogramming, targeting urocanate hydratase 1 as a novel therapeutic approach in colorectal cancer**  
 Amir Avan (School of biomedical sciences, Queensland University of Technology)

MO53-3 **Evaluating ABBV-400 with fluorouracil, folinic acid, and bevacizumab in previously treated patients with mCRC**  
 Akihito Kawazoe (National Cancer Center Hospital East)  
**治療歴のある mCRC 患者を対象とした ABBV-400 とフルオロウラシル、フォリン酸及びベバシズマブの併用療法**  
 川添 彬人 (国立がん研究センター東病院)

MO53-4 **Efficacy of Oxaliplatin in metastatic colorectal cancer with the amplification of Chr20q11.21**  
 Shohei Ueno (Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University)  
**Chr20q11.21 の増幅を有する大腸癌におけるオキサリプラチンの有効性**  
 上野 翔平 (九州大学大学院 医学研究院 病態修復内科)

MO53-5 **Potential Therapeutic Targets in Small Bowel Adenocarcinoma: Expression of Claudin 18.2, Nectin-4, HER3, and PD-L1**  
 Hiroyuki Fujii (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)  
**小腸腺がんにおける新規治療標的の検討 :Claudin 18.2, Nectin-4, HER3, PD-L1 の免疫組織化学染色解析**  
 藤井 博之 (国立がん研究センター中央病院)

14:00-15:00 Mini Oral Session 54

**MO54** Gastrointestinal Cancer 7 (Colorectal Cancer 2, Trial) E  
 消化管 7 (大腸 2 臨床)

Chairs : Wataru Ichikawa (Division of Medical Oncology, Showa University Fujigaoka Hospital)  
 Toshiaki Masuishi (Department of Clinical Oncology, Aichi Cancer Center Hospital)  
 司会 : 市川 度 (昭和大学藤が丘病院腫瘍内科・緩和医療科)  
 舩石 俊樹 (愛知県がんセンター薬物療法部)

MO54-1 **Analysis of major cardiovascular events in metastatic gastrointestinal cancer: Tokushukai Real World Data Project 07**  
 Rai Shimoyama (Department of general surgery, Shonan Kamakura General Hospital)  
**転移性消化管癌における主要心血管イベントの頻度および予後の解析 : 徳洲会リアルワールドデータ・プロジェクト (TREAD07)**  
 下山 ライ (湘南鎌倉総合病院 外科)

MO54-2 **Encorafenib, binimetinib and cetuximab therapy for BRAF-mutated mCRC with prognostic factors: BEETS trial (JACCRO CC-18)**  
 Kunishige Koga (Division of Gastroenterology, Chiba Cancer Center)  
**リスク因子を有する BRAF 変異型大腸癌に対するエンコラフェニブ、ビニメチニブ、セツキシマブ併用療法 : BEETS 試験 (JACCRO CC-18)**  
 古賀 邦林 (千葉県がんセンター 消化器内科)

MO54-3 **A multicenter trial to evaluate the safety and efficacy of FOLFOX therapy in cancer patients undergoing hemodialysis**

Hisateru Yasui (Department of Medical Oncology, Kobe City Medical Center General Hospital)

**血液透析中の消化器癌患者に対する FOLFOX 療法の安全性と有効性に関する多施設共同臨床試験**

安井 久晃 (神戸市立医療センター中央市民病院腫瘍内科)

MO54-4 **The efficacy of trifluridine/tipiracil plus chemotherapy in mCRC : multi-center prospective study in Taiwan**

Hung-chih Hsu (Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan)

MO54-5 **A phase II trial of aflibercept plus FOLFIRI in colorectal cancer after anti-EGFR agents (HGCSG1801): updated analyses**

Kazuaki Harada (Department of Gastroenterology and Hepatology, Hokkaido University Hospital)

**抗 EGFR 抗体薬不応の結腸直腸癌に対する FOLFIRI+ アフリベルセプトの有効性と安全性を検討する第 II 相試験 (HGCSG1801): Update 解析**

原田 一顕 (北海道大学病院 消化器内科)

15:00-16:00 Mini Oral Session 55

**MO55** Gastrointestinal Cancer 8 (Colorectal Cancer 3, Other Retro)  
消化管 8 (大腸 3・その他 レトロ)

**E**

Chairs : Keisho Chin (Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research)

Atsuo Takashima (Department of Gastrointestinal Oncology, National Cancer Center Hospital)

司会 : 陳 勁松 (がん研有明病院消化器化学療法科)

高島 淳生 (国立がん研究センター中央病院 消化管内科)

MO55-1 **Real-world evidence on genomic profiles and survival outcomes in HER2-positive metastatic colorectal cancer**

Yuki Matsubara (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)

**臨床ゲノムデータベースに基づく切除不能 HER2 陽性大腸癌に関するリアルワールドデータ解析**

松原 裕樹 (国立がん研究センター東病院 消化管内科)

MO55-2 **A retrospective analysis of the efficacy and safety of immune checkpoint inhibitors for MSI-high solid tumors**

Ryunosuke Numakura (Department of Medical Oncology, Tohoku University Hospital)

**MSI-High 固形癌における免疫チェックポイント阻害薬の治療成績の後方視的解析**

沼倉 龍之助 (東北大学病院 腫瘍内科)

MO55-3 **Survival of Colorectal Cancer with Adnexal or Ovarian Metastasis after Metastectomy and Chemotherapy: A Meta-Analysis**

Andree Kurniawan (Internal Medicine, Faculty of Medicine, Pelita Harapan University)

MO55-4 **Trifluridine/Tipiracil (FTD/TPI) in Metastatic Colorectal Cancer in Hong Kong: A Territory-Wide Cohort Study**

Hoi Lam Karen Li (Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Room 14  
Meet the Experts  
Poster

- 
- MO55-5 **Real world data for plasma concentrations of imatinib in elderly patients with gastrointestinal stromal tumor**  
Takuma Suzuki (National Cancer Center Hospital Department of Pharmacy)  
**高齢 GIST 患者におけるイマチニブ血漿中濃度のリアルワールドデータ**  
鈴木 拓真 (国立研究開発法人 国立がん研究センター中央病院 薬剤部)
- 
- MO55-6 **Analysis of arterial thromboembolism in metastatic gastrointestinal cancer: Tokushukai Real World Data Project (TREAD07)**  
Rai Shimoyama (Department of general surgery, Shonan Kamakura General Hospital)  
**転移性消化管癌における動脈血栓塞栓症の頻度とその予後の解析：徳洲会リアルワールドデータ・プロジェクト (TREAD07)**  
下山 ライ (湘南鎌倉総合病院 外科)

## 第13会場 (神戸国際展示場 2号館2階 2A会議室)

8:30-9:20 Mini Oral Session 56

**MO56** Rare Cancer / Cancer of Unknown Primary 3 (Sarcoma)  
希少がん3 (原発不明がん・肉腫)

**E**

Chairs : Shunji Takahashi (Department of Genomic Medicine and Department of Medical Oncology, Cancer Institute Hospital)  
Toshio Kubo (Department of Allergy and Respiratory Medicine, Okayama University Hospital)  
司会 : 高橋 俊二 (がん研有明病院ゲノム診療部、総合腫瘍科)  
久保 寿夫 (岡山大学病院 呼吸器・アレルギー内科)

### MO56-1 Clinical potential of comprehensive genome profiling for sarcoma treatment: a single center prospective study

Tomohiro Kubo (Department of Medical Oncology, Sapporo Medical University School of Medicine)

肉腫治療における包括的がんゲノムプロファイリングの臨床的可能性  
久保 智洋 (Sapporo Medical University School of Medicine)

### MO56-2 Genetic alterations of p53 gene in advanced STS and its association with clinical parameters in Indian population

Muzamil A Mir (Department of Pathology, All India Institute of Medical Science, New Delhi)

### MO56-3 Genomic landscape and clinical features of inflammatory myofibroblastic tumor : analysis using the database of Japan

Rika Moku (Department of Medical Oncology, Hokkaido University Hospital)

炎症性筋線維芽細胞腫瘍のゲノム情報と臨床的特徴 : 日本のデータベースを用いた解析  
杵 里花 (北海道大学病院 腫瘍内科)

### MO56-4 Evaluating the Efficacy of PD-L1 Inhibitors in Treating Angiosarcoma: A Systematic Review

Michelle A Hutapea (Faculty of Medicine, Pelita Harapan University)

### MO56-5 Myoepithelial carcinoma of soft tissues and bone

Hisaki Aiba (Nagoya City University)

骨軟部発生の筋上皮癌の臨床成績  
相羽 久輝 (名古屋市立大学病院)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Room 14  
Meet the Experts  
Poster

14:00-15:50 Oral Session 17

**017** Rare Cancer / Cancer of Unknown Primary  
希少がん・原発不明がん



Chairs : Toshihiro Kudo (Osaka International Cancer Institute)  
Masanobu Takahashi (Department of Clinical Oncology, Tohoku University Graduate School of Medicine)

Discussants : Kohichi Takada (Department of Medical Oncology, Sapporo Medical University School of Medicine)  
Hiroshi Urakawa (Department of Advanced Medicine, Nagoya University Hospital)

司会 : 工藤 敏啓 (大阪国際がんセンター)  
高橋 雅信 (東北大学大学院医学系研究科臨床腫瘍学分野)

ディスカッサント : 高田 弘一 (札幌医科大学医学部腫瘍内科学講座)  
浦川 浩 (名古屋大学医学部附属病院先端医療開発部)

017-1 **Deep Learning-Based Analysis of Metabolic Networks and TME Interactions in Pancreatic Neuroendocrine Tumors**  
Elfiany Syafruddin (Computational Biology and Medicine Laboratory, University of L'Aquila)

017-2 **SIRT4 has a pro-proliferative role in human melanoma**  
Md Shariful Islam (Department of Dermatology, University of Wisconsin-Madison, USA)

017-3 **Phase II trial on nivolumab plus radiotherapy in patients with metastatic mucosal melanoma: PORTER-M3 trial**  
Tomoya Yokota (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)  
**転移性粘膜黒色腫に対する Nivolumab + Radiotherapy の第 II 相臨床試験**  
横田 知哉 (静岡県立静岡がんセンター)

017-4 **Molecular landscape of neuroendocrine neoplasms using tissue and blood-based genotyping in MONSTAR-SCREEN-2**  
Shinpei Ushiyama (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)  
**MONSTAR-SCREEN-2 における組織および血液に基づく遺伝子解析を用いた神経内分泌腫瘍の分子学的特徴**  
牛山 心平 (国立がん研究センター東病院消化管内科)

017-5 **Outcomes of chemotherapy for unresectable gastroenteropancreatic and primary unknown neuroendocrine tumor G3**  
Hiroyuki Okuyama (Department of Medical Oncology, Kagawa University Hospital)  
**切除不能消化器・原発不明神経内分泌腫瘍 G3(NET G3) に対する薬物療法の治療成績**  
奥山 浩之 (香川大学医学部附属病院 腫瘍内科)

017-6 **PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Advanced Solid Tumors With a SMARCA4 Mutation: Phase 1 Trial**  
Timothy A Yap (Department of Investigational Cancer Therapies, The University of Texas, MD Anderson Cancer Center)

**M057** Cross-sectional Program 3  
臓器横断プログラム 3

**E**

Chairs : Takaaki Tokito (Division of Respiriology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine)  
Kazuki Sudo (National cancer center hospital)  
司会 : 時任 高章 (久留米大学医学部内科学講座呼吸器神経膠原病内科)  
須藤 一起 (国立がん研究センター中央病院)

**M057-1** Real-World Data Analysis of Hematological Immune-Related Adverse Events  
**Encore** Post-Immune Checkpoint Inhibitors

Yusuke Kamihara (Department of Hematology, School of Medicine, University of Toyama)  
**免疫チェックポイント阻害薬投与後に発生した血液学的免疫関連有害事象のリアルワールドデータ解析**  
神原 悠輔 (富山大学 学術研究部医学系 血液内科)

**M057-2** Analysis of Clinical Features of Immune Checkpoint Inhibitor-Induced Adrenocortical Insufficiency

Masaaki Yanai (Cancer Center, Tottori University Hospital)  
**免疫チェックポイント阻害薬による副腎皮質機能低下症の臨床的特徴に関する検討**  
矢内 正晶 (鳥取大学医学部附属病院 がんセンター)

**M057-3** ICOS+ CD4 T cells and CXCL13 are predictive factors for the development of anti-PD-(L)1 therapy-induced pneumonitis

Mari Yokoi (Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University)  
**末梢血中の ICOS+ CD4 T 細胞及び CXCL13 の変化は、抗 PD-(L)1 療法誘発性間質性肺炎患の発症予測因子となり得る**  
横井 菜里 (京都大学大学院 医学研究科 附属がん免疫総合研究センター がん免疫治療臨床免疫学部門)

**M057-4** Cytokine release syndrome from immune checkpoint blockade in patients with cancer: FAERS analysis

Yu Fujiwara (Roswell Park Comprehensive Cancer Center)  
**免疫チェックポイント阻害薬併用療法によるサイトカイン放出症候群の臨床的特徴 :FDA 有害事象報告システムを用いた解析**  
藤原 裕 (Roswell Park Comprehensive Cancer Center)

**M057-5** Investigation of Antibodies and Their Impact on Efficacy and Adverse Events in Patients on Immune Checkpoint Inhibitors

Asuka Okada (Respiratory Medicine, Saiseikai Suita Hospital)  
**固形癌に対する ICI 療法を受けた患者における各種抗体と治療効果や副作用の検討**  
岡田 あすか (大阪府済生会吹田病院 呼吸器内科)

**M057-6** HRT-Induced Exosomal lncRNAs as Predictors of ICI Resistance in Melanoma Using Machine Learning for Transgender Patients

Rifaldy Fajar (Department of Mathematics and Computer Science, Karlstad University)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

## Meet the Experts ① (神戸ポートピアホテル 南館 B1 階 ローズ・アイリス)

8:30-9:30 Meet the Experts 12

**ME12** New Phase in Brain Tumor Treatment - Precision Therapy, Gene Therapy, International Collaboration  
脳腫瘍治療の新フェーズ—Precision Therapy、遺伝子治療、国際コラボレーション



Facilitator : Kazuki Sudo (Department of Medical Oncology, National Cancer Center Hospital)  
司会 : 須藤 一起 (国立がん研究センター中央病院 腫瘍内科)

**ME12** New Phase in Brain Tumor Treatment - Precision Therapy, Gene Therapy, International Collaboration

Kazuhiko Kurozumi (Department of Neurosurgery, Hamamatsu University School of Medicine)  
脳腫瘍治療の新フェーズ—Precision Therapy、遺伝子治療、国際コラボレーション  
黒住 和彦 (浜松医科大学 脳神経外科)

10:30-11:30 Meet the Experts 13

**ME13** Patient-Centered Care for adolescents and young adults with cancer



Facilitator : Saiko Kurosawa (Department of Oncology, Ina Central Hospital)  
司会 : 黒澤 彩子 (伊那中央病院 腫瘍内科)

**ME13** Patient-Centered Care for adolescents and young adults with cancer

Bradley J. Zebrack (University of Michigan Rogel Cancer Center and School of Social Work)

14:00-15:00 Meet the Experts 14

**ME14** Challenges with biomarker-based therapy development



Facilitator : Hitomi Sakai (Advanced Cancer Translational Research Institute, Showa University)  
司会 : 酒井 瞳 (昭和大学 先端がん治療研究所)

**ME14** Challenges with biomarker-based therapy development

Carlos H Barrios (Latin American Cooperative Oncology Group, LACOG)



## Meet the Experts ② (神戸ポートピアホテル 南館 B1 階 カトリア・ライラック)

8:30-9:30 Meet the Experts 15

### ME15 State of the art, perspectives and challenges in NSCLC oncogene addiction

E

Facilitator: Yuichi Tambo (Respiratory Medicine, Kanazawa University Hospital)  
司会: 丹保 裕一 (金沢大学附属病院 呼吸器内科)

### ME15 State of the art, perspectives and challenges in NSCLC oncogene addiction

Solange Peters (Lausanne University Hospital)

10:30-11:30 Meet the Experts 16

### ME16 Future of metastatic prostate cancer

E

Facilitator: Aiko Maejima (Department of Medical Oncology/Urology, National Cancer Center Hospital)  
Akiyuki Yamamoto (Department of Urology, Toyohashi Municipal Hospital)  
司会: 前嶋 愛子 (国立がん研究センター中央病院 腫瘍内科、泌尿器・後腹膜腫瘍科)  
山本 晃之 (豊橋市民病院 泌尿器科)

### ME16 Future of metastatic prostate cancer

Axel Stuart Merseburger (University of Lübeck)

15:30-16:30 Meet the Experts 17

### ME17 The career development of female oncologists in the United States

E

Facilitator: Hirokazu Ogino (Department of Respiratory Medicine & Rheumatology, Tokushima University Hospital)  
司会: 荻野 広和 (徳島大学病院 呼吸器・膠原病内科)

### ME17 The career development of female oncologists in the United States

Ticiana Leal (Emory University)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

ポスター① (神戸国際展示場 2号館 1階 コンベンションホール)

13:05-13:50 Poster Session 76

P76 Gastrointestinal Cancer 9 (Case Report 3)  
消化管 9 (ケースレポート 3)

- P76-1 **A case of MSI-high transverse colon cancer with KRASG12S and BRAFV600E mutation successfully treated with pembrolizumab**  
Toshihiko Matsumoto (Medical oncology, Ichinomiya nishi hospital)  
**ペムブロリズマブ投与が著効した KRASG12S 変異陽性 /BRAFV600E 陽性 /MSI-high 横行結腸癌の 1 例**  
松本 俊彦 (一宮西病院 腫瘍内科)
- P76-2 **A case of metastatic colorectal cancer with intratumor RAS heterogeneity**  
Yota Kusumoto (Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center)  
**組織内の RAS 遺伝子の遺伝学的不均一性を示唆する転移性大腸がんの一例**  
楠本 洋太 (九州がんセンター消化管・腫瘍内科)
- P76-3 **Sigmoid Colon Cancer with Peritoneal Dissemination Achieving PR After SEMS and Bevacizumab + mFOLFOX6 Therapy**  
Yuki Tateno (Department of Surgery)  
**SEMS 留置後に Bevacizumab+mFOLFOX6 療法を行い PR を得た腹膜播種を伴う S 状結腸癌の 1 例**  
館野 佑樹 (東京都立多摩南部地域病院)
- P76-4 **A Case of Rectal Primary Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm (MiNEN) with Diagnostic Challenges**  
Koji Ide (Department of medicine and biosystemic science, Kyushu university faculty of medicine)  
**診断に苦慮した直腸原発 mixed neuroendocrine-non-neuroendocrine neoplasm(MiNEN) の 1 例**  
井手 宏二 (九州大学大学院 医学研究院 病態修復内科)
- P76-5 **A case of dramatic response to Pembrolizumab in MSI-high UR colorectal cancer diagnosed following abdominal hemorrhage**  
Takashi Matsumoto (Department of Surgery Izumi General Hospital)  
**SAM による腹腔内出血を契機に診断された MSI-High 切除不能大腸癌に対して Pembrolizumab 単剤が著効した症例**  
松本 嵩史 (出水総合医療センター)
- P76-6 **UTILIZING ctDNA TO DISTINGUISH BETWEEN MALIGNANT AND BENIGN PULMONARY LESIONS IN RECTAL CANCER FOLLOW-UP: A CASE REPORT**  
Thu H Nguyen (Franco-Vietnamese Hospital, Hy Vong Cancer Centre)
- P76-7 **A case of long-term disease control with nivolumab monotherapy for MSI-H metastatic colorectal cancer**  
Miyuki Takahashi (National Hospital Organization Disaster Medical Center, Department of Gastroenterological and Breast Surgery)  
**MSI-H 再発大腸癌に対しニボルマブ単剤で長期に病勢コントロールを得ている一例**  
高橋 深幸 (災害医療センター 消化器乳腺外科)

- P76-8 **FATAL SPONTANEOUS TUMOR LYSIS SYNDROME IN A YOUNG FILIPINO MALE WITH METASTATIC RECTAL ADENOCARCINOMA: A CASE REPORT**  
Felix Gabriel Salinas (Southwestern University Medical Center)
- P76-9 **A response case of TMB-high colon cancer diagnosed by the second gene panel test treated with regorafenib and nivolumab**  
Nobuhiro Tsuruta (Tsuruta clinic)  
当初 FoundationOne®CDx で TMB-Low であった MSS 大腸癌への新たな Guardant360® がん遺伝子パネル検査で TMB-High となり、Regorafenib+Nivolumab 療法にて抗腫瘍効果を得た一例  
鶴田 展大 (鶴田クリニック)
- P76-10 **7 cases of encorafenib + binimetinib + cetuximab therapy for BRAF V600E gene mutation-positive colorectal cancer**  
Sachiko Nagasu (Multidisciplinary Treatment Cancer Center, Kurume University Hospital)  
**BRAF V600E 遺伝子変異陽性大腸癌に対するエンコラフェニブ + ビニメチニブ + セツキシマブ療法を施行した 7 例の報告**  
長主 祥子 (久留米大学病院 がん集学治療センター)
- 13:05-13:50 Poster Session 77
- P77** Gastrointestinal Cancer 10 (Colorectal Cancer 3)  
消化管 10 (大腸 3)
- P77-1 **The salvage line treatment after progression on anti-EGFR mAb for RAS/BRAF wild-type metastatic colorectal cancer**  
**Encore**  
Emiko Tange (Department of Gastroenterological Chemotherapy)  
抗 EGFR 抗体薬不応の RAS/BRAF 野生型切除不能・進行再発大腸癌における最適な後方治療の治療戦略の検討  
丹下 絵美子 (がん研究会有明病院)
- P77-2 **Comparison between bevacizumab and ramucirumab in 2nd-line chemotherapy with FOLFIRI for metastatic colorectal cancer**  
Mika Kitagawa (gastroenterology)  
切除不能大腸癌セカンドラインにおける FOLFIRI 併用 ベパシズマブとラムシルマブの比較  
北川 美香 (名古屋市立大学大学院医学研究科 消化器・代謝内科学)
- P77-3 **The efficacy and safety of encorafenib, binimetinib and cetuximab in BRAF V600E-mutated metastatic colorectal cancer**  
Hiroaki Takagi (Department of Medical Oncology, Toyama Prefectural Central Hospital)  
BRAFV600E 変異進行大腸癌に対するエンコラフェニブ + ビニメチニブ + セツキシマブ併用化学療法の安全性と有効性の検討  
高木 宏明 (富山県立中央病院 腫瘍内科)
- P77-4 **AI subtype characterization using histological slide images for colon adenocarcinoma: Patholomics approach**  
Eva Cheung (University of Hong Kong)
- P77-5 **Development of Machine Learning Model Platelet-Index Based Scoring (PIBS) Application to Predict Colorectal Cancer Stage**  
Citra Aryanti (hasanuddin university)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P77-6 **Cetuximab plus FOLFOX as first-line chemotherapy for metastatic colorectal cancer: A 10-year real world data analysis**  
 Yukari Suzuki (Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research)  
**転移性大腸癌における一次治療 FOLFOX+Cetuximab 併用療法に関する検討: 当院での 10 年間のリアルワールドデータ解析**  
 鈴木 由佳理 (がん研究会有明病院)

P77-7 **Influence of the type of anatomic resection on anastomotic leak after surgery for colon cancer**  
**Encore**  
 Suat Chin Ng (Eastern Health)

P77-8 **Impact of pre-treatment VEGF inhibitors on the safety and efficacy of FTD/TPI plus BEV in metastatic colorectal cancer**  
 Koshiro Fukuda (Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)  
**切除不能大腸癌における FTD/TPI+BEV の安全性・有効性に対する前治療としての VEGF 阻害薬の影響について**  
 福田 晃史郎 (がん研究会有明病院 消化器化学療法科)

P77-9 **Efficacy and Safety of Anti HER2 therapy for metastatic colorectal cancer patients with HER2 amplification**  
 Hiroko Hasegawa (Department of Hepatology and Gastroenterology, NHO Osaka National Hospital)  
**当院における HER2 陽性大腸癌における trastuzumab + pertuzumab 療法の治療成績**  
 長谷川 裕子 (大阪医療センター 消化器内科)

P77-10 **Matching-Adjusted Indirect Comparison of Sotorasib + Panitumumab vs. Trifluridine/Tipiracil + Bevacizumab in mCRC**  
**Encore**  
 Yasutoshi Kuboki (Experimental Therapeutics and GI Oncology Department, National Cancer Center Hospital East)  
**転移性大腸癌患者におけるソトラシブ及びパニツムマブ併用治療とトリフルリジン/チピラシル及びベバシズマブ併用療法との間接比較**  
 Yasutoshi Kuboki (National Cancer Center Hospital East)

13:05-13:50 Poster Session 78

**P78** Gastrointestinal Cancer 11 (Colorectal Cancer 4)  
 消化管 11 (大腸 4)

P78-1 **Targeting PI3K/AKT signaling pathway Inhibits Cell Growth and Induces Apoptosis in Colorectal Cancer Cells**  
 Seyed Mahdi Hassanian Mehr (Dept of Medical Biochemistry, mashhad universityof medical sciences)

P78-2 **SEPTIN 9 Methylation as Colorectal Cancer Recurrence Predictor: A Systematic Review and Meta-Analysis**  
 Ngakan Putu Krishna Mahayana (Faculty of Medicine, Udayana University)

- P78-3 **Chemoradiotherapy with 5-FU plus mitomycin for patients with squamous cell carcinoma of the anal canal**  
Natsuko Murase (Department of Medical Oncology and Hematology, Kobe University Hospital)  
**肛門扁平上皮癌に対する 5-FU/MMC における化学放射線療法の臨床成績**  
村瀬 奈津子 (神戸大学医学部附属病院 腫瘍・血液内科)
- P78-4 **Clinical significance of comprehensive genomic profiling in metastatic colorectal cancer by RAS/BRAF status**  
Kazuki Ogawa (Department of Clinical Oncology, St. Marianna University School of Medicine)  
**進行性大腸癌に対する RAS/BRAF 変異別の CGP 検査の臨床的意義**  
小川 和起 (聖マリアンナ医科大学 臨床腫瘍学)
- P78-5 **Analysis of Prognostic Factors on Trifluridine-Tipiracil Plus Bevacizumab Treatment in Metastatic Colorectal Cancer**  
Mai Onishi (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)  
**切除不能進行・再発大腸癌におけるトリフルリジン・チピラシルとベパシズマブ併用療法の予後因子解析**  
大西 舞 (国立がん研究センター中央病院 消化管内科)
- P78-6 **Evaluating anticancer effects of newly isolated lactic acid bacteria in cellular and animal models of colorectal cancer**  
Elnaz Ghorbani (Department of Medical Microbiology and virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran)
- P78-7 **A multicenter retrospective study on clinical feature of patients with HER2-positive colorectal cancer (HGCSG2304)**  
Shiho Kaneko (Division of Cancer Center, Hokkaido University Hospital)  
**HER2 陽性大腸癌の臨床的特徴に関する多施設共同後ろ向き研究 (HGCSG2304)**  
金子 志帆 (北海道大学病院 腫瘍センター)
- P78-8 **Therapeutic Potential of Targeting the Cytochrome P450 Enzymes Using Lopinavir/Ritonavir in Colorectal Cancer**  
Amir Avan (School of biomedical sciences, Queensland University of Technology)
- P78-9 **Withdrawn**
- P78-10 **TAS-102 combinations demonstrated significant better outcome compared to regorafenib combinations for mCRC patients**  
Yi-hsin Liang (National Taiwan University Hospital)

13:05-13:50 Poster Session 79

**P79** Gastrointestinal Cancer 12 (Gastric Cancer 4)  
消化管 12 (胃 4)

- P79-1 **A case of advanced gastric cancer with multiple intragastric lesions presenting different MSI and MMR status**  
Genju Koh (Internal medicine, Yao Tokushukai General Hospital)  
**胃内の複数病変および転移病変に MSI status および MMR 蛋白の発現に相異が見られた AFP 産生進行胃癌**  
洪 鉉寿 (八尾徳洲会総合病院 内科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

- P79-2** **Impact of neoadjuvant chemoradiotherapy/chemotherapy (NACRT/NACT) on anastomotic complications in gastric cancer**  
 Shagun Misra (Department of Radiotherapy Sanjay Gandhi Postgraduate Institute Of Medical Sciences)
- 
- P79-3** **Trastuzumab, chemotherapy and immunotherapy in HER2 + locally advanced or metastatic gastroesophageal cancer**  
**Encore**  
 Lorenz Fort E Revillas (St. Luke's Medical Center)
- 
- P79-4** **Investigation of peritoneal recurrence factors in surgical cases of gastric cancer with CY1, P0**  
 Hiroto Tanaka (First Department of Surgery)  
**CY1P0 胃癌手術例における腹膜再発因子の検討**  
 田中 寛人 (山梨大学医学部 第一外科)
- 
- P79-5** **Correlation between irAEs and efficacy of Nivo-CT for advanced gastric or GEJ cancer: a multi-center retrospective study**  
 Nozomu Ogura (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)  
**進行胃癌または胃食道接合部癌に対するニボルマブ + 化学療法における免疫関連有害事象と臨床アウトカムとの関連: 多施設共同後方視的研究**  
 小倉 望 (国立がん研究センター中央病院 消化管内科)
- 
- P79-6** **Prognostic change after nivolumab approval as first-line chemotherapy in patients with metastatic gastric cancer**  
 Shun Takahashi (Internal medicine)  
**切除不能胃癌 1 次治療における Nivolumab 承認前後の予後検討**  
 高橋 惇 (釧路労災病院 内科)
- 
- P79-7** **Efficacy of PTX+RAM and nab-PTX+RAM for advanced gastric cancer with and without peritoneal dissemination**  
 Hiroataka Uno (Department of Gastroenterology, University of Tsukuba Hospital)  
**進行胃癌に対する PTX+RAM と nab-PTX+RAM の腹膜播種別の実臨床効果**  
 宇野 広隆 (筑波大学附属病院 消化器内科)
- 
- P79-8** **Analysis of H. pylori infection status and clarithromycin-resistant strains in patients with gastric MALT lymphoma**  
 Jaehyuk Lee (Chonnam National University Medical School)
- 
- P79-9** **The clinical impact of FTD/TPI + RAM in Advanced Gastric Cancer - A Multicenter Retrospective Study (HGCSG2302)**  
**Encore**  
 Iori Motoo (Third Department of Internal Medicine, University of Toyama)  
**進行 / 再発胃癌に対する FTD/TPI+RAM 療法の多施設共同後方視的観察研究 (HGCSG2302)**  
 元尾 伊織 (富山大学附属病院)

**P80** Hepatobiliary / Pancreatic Cancer 7 (Biliary Tract Cancer 1)  
 肝胆腫7 (胆道 1)

- P80-1 Identification of Prognostic Genetic Biomarkers in Biliary Tract Cancer Using a Novel Gene Panel**  
 Shun Fujiwara (Department of Medical Oncology, Institute of Science Tokyo hospital)  
**新規遺伝子パネルを用いた胆道癌における予後予測遺伝子バイオマーカーの同定**  
 藤原 俊 (東京科学大学 臨床腫瘍科)
- P80-2 Efficacy and safety of EUS-guided hepaticogastrostomy for malignant biliary obstruction in patients with ascites**  
 Yuno Goto (Third Department of internal medicine, University of Toyama)  
**腹水を伴う悪性胆道狭窄に対する EUS-HGS の有効性と安全性の検討**  
 後藤 柚乃 (University of Toyama)
- P80-3 Validation of the pancreatoduodenectomy for elderly patients with distal cholangiocarcinoma in terms recurrence**  
 Wataru Izumo (Department of Digestive Surgery, University of Yamanashi Hospital)  
**再発の観点から見た高齢者遠位胆管癌患者に対する膵頭十二指腸切除術の意義の検討**  
 出雲 渉 (山梨大学医学部附属病院)
- P80-4 The study of chromosome abnormality pattern of cholangiocarcinoma patient with cisplatin response**  
 Sutteemon Techa-ay (Cholangiocarcinoma Screening and Care Program (CASCAP), Khon Kaen University)
- P80-5 A real-world data of the comprehensive genomic profiling testing in patients with biliary tract cancer**  
 Iori Motoo (Third Department of Internal Medicine, University of Toyama)  
**胆道癌における包括的がんゲノムプロファイリング検査の現状**  
 元尾 伊織 (富山大学附属病院 第三内科)
- P80-6 Adjustment of GEM and CDDP based on eGFR is crucial for outcomes and renal preservation in biliary tract cancer**  
 Takanori Masumoto (Department of Gastroenterology and Hepatology, Osaka General Medical Center)  
**胆道癌患者において eGFR に基づき GEM+CDDP 併用療法の投与法を調整することは、治療成績および腎保護において有用である**  
 増本 貴紀 (大阪急性期・総合医療センター 消化器内科)

**P81** Hepatobiliary / Pancreatic Cancer 8 (Biliary Tract Cancer 2)  
 肝胆腫8 (胆道 2)

- P81-1 Risk factors for recurrence in patients with resected biliary tract cancer treated with S-1 as adjuvant chemotherapy**  
 Tomonao Taira (Department of Hepatobiliary and Pancreatic Oncology)  
**術後補助化学療法として S-1 治療を受けた胆道癌切除患者における再発リスク因子の検討**  
 平 知尚 (国立がん研究センター東病院)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Room 14  
Meet the Experts  
Poster

- P81-2 **Impact of thyroid-stimulating hormone change on durvalumab, gemcitabine and cisplatin therapy for biliary tract cancer**  
 Michinori Matsumoto (Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine)  
**甲状腺刺激ホルモンの変化が進行胆道癌に対するデュルバルマブ、ゲムシタビン、およびシスプラチン療法の無増悪生存期間に与える影響**  
 松本 倫典 (東京慈恵会医科大学 外科学講座 肝胆膵外科)
- 
- P81-3 **Real-World Efficacy of Gemcitabine, Cisplatin, and Durvalumab in Advanced BTC: Incidence of Conversion Surgery**  
 Masaki Kawabata (Hepatobiliary and Pancreatic Medicine)  
**進行胆道癌における GCD 療法の有効性、コンバージョン手術についての検討**  
 川端 将生 (大阪国際がんセンター 肝胆膵内科)
- 
- P81-4 **Comparison of GCD vs. GCS Regimens for Unresectable Biliary Tract Cancer: A Retrospective Study**  
 Hiroki Yukami (Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University)  
**切除不能胆道癌に対する GCD 療法と GCS 療法の比較 : 後ろ向き研究**  
 由上 博喜 (大阪医科大学薬科大学病院 化学療法センター)
- 
- P81-5 **The Ideal Second-Line Treatment for Patients with Advanced Biliary Tract Cancer : A Network-Meta Analysis**  
 Erwin Syarifuddin (hasanuddin university)
- 
- 13:05-13:50 Poster Session 82
- 
- P82** Hepatobiliary / Pancreatic Cancer 9 (Pancreatic Cancer 3)  
 肝胆膵 9 (臓臓 3)
- 
- P82-1 **Exploring genetic characteristics of pancreatic cancer with minor KRAS mutations**  
 Takaaki Furukawa (Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research)  
**マイナー KRAS 変異を有する膵癌における遺伝学的特徴の探索**  
 古川 貴光 (がん研究会有明病院 肝胆膵内科)
- 
- P82-2 **Total Lesion Glycolysis as a Prognostic Factor for Pancreatic Cancer**  
 Calvin Tjguito (Pelita Harapan University, Faculty of Medicine)
- 
- P82-3 **Timing and Conditions of Liquid Biopsy Submission and Its Effect on Genomic Profiling in Advanced Pancreatic Cancer**  
 Makiko Urabe (Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute)  
**進行膵癌におけるリキッドバイオプシー実施のタイミングと条件についての検討**  
 占部 真貴子 (大阪国際がんセンター)
- 
- P82-4 **Clinical and pathological features of SWI/SNF chromatin remodeling complex deficiency in anaplastic pancreatic cancer**  
 Joji Muramatsu (Department of Medical Oncology, Sapporo Medical University School of Medicine)  
**退形成性膵癌における SWI/SNF クロマチンリモデリング複合体欠損の臨床病理学的特徴の検討**  
 村松 丈児 (札幌医科大学医学部腫瘍内科学講座)



- P82-5 **LNCRNA Linc00337 functions as an E2F1 co-activator and promotes cell proliferation in pancreatic ductal adenocarcinoma**  
Huakai Wang (Shanghai Key Laboratory of Biliary Tract Disease Research, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine)
- P82-6 **The Role of SMAD4 and P15 gene expression on Patients with Pancreatic Ductal Adenocarcinoma and its Cancer Staging**  
Mikael Harkingto Wibisono (Faculty of Medicine, Pelita Harapan University)
- P82-7 **Adenosine catalyzing enzyme CD73 suppress CD8+ T cell infiltration resulting in poor prognosis in PDAC**  
Eriko Katsuta (Institute of Science Tokyo)  
**膵癌における細胞外アデノシン触媒酵素 CD73 は腫瘍内への CD8+T 細胞浸潤を抑制し予後不良に寄与**  
勝田 絵里子 (東京科学大学)
- P82-8 **Infection Risk and Prolonged Survival in Pancreatic Cancer Patients: How do Socioeconomic Effect Overall Outcome?**  
Yesika Simbolon (Atmajaya University)
- 13:05-13:50 Poster Session 83
- P83** Translational Research / Clinical Pharmacology 7 (Other 1)  
TR・臨床薬理 7 (その他 1)
- P83-1 **The therapeutic potentials of novel nano form of curcumin against post-surgical adhesion bands**  
Seyed Mahdi Hassanian Mehr (Dept of Medical Biochemistry, mashhad university of medical sciences)
- P83-2 **Real-world data of plasma-based comprehensive genomic profiling assays by Guardant360 CDx in advanced lung cancer**  
Masaki Ishida (Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajii-cho, Kamigyo-ku, Kyoto, Japan)  
**進行肺癌におけるリキッドバイオプシー検査の有用性**  
石田 真樹 (京都府立医科大学附属病院)
- P83-3 **Comparison of the latest regulations and implementation status of companion diagnostics in Japan, USA, and EU**  
Ryo Miyata (Novartis Pharma K.K.)  
**日米欧におけるコンパニオン診断薬の最新の規制比較及び運用状況**  
宮田 亮 (ノバルティス ファーマ株式会社)
- P83-4 **mRNA-LNP vaccination-based immunotherapy augments CD8+ T cell responses against HPV-positive oropharyngeal cancer**  
Ke Qiu (West China Hospital, Sichuan University)  
**Encore**
- P83-5 **Integration of Biochemical Parameter and CAP Scores for Assessing Disease Severity and Progression in NAFLD**  
Hina Parveen (King George medical university)
- P83-6 **Imaging of carbon nanodots with PARP inhibitor for overcoming drug resistance**  
Yingqiu Xie (Department of Biology, School of Sciences and Humanities, Nazarbayer University)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Room 14  
Meet the Experts  
Poster

P83-7 **Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer**  
 Yoshihito Morimoto (Center for Education and Research on Clinical Pharmacy, Showa Pharmaceutical University)  
**膵臓がんに対する S-1 と経口 ATR 阻害薬 ceralasertib の併用効果に関する基礎的検討**  
 森元 能仁 (昭和薬科大学 臨床薬学教育研究センター)

13:05-13:50 Poster Session 84

**P84** Translational Research / Clinical Pharmacology 8 (Other 2)  
 TR・臨床薬理 8 (その他 2)

P84-1 **Next Generation Sequencing Gene Mutational Analysis and Therapeutic Implications among Filipinos: A retrospective study**  
 Herdee Gloriane C Luna (National Kidney and Transplant Insitute)

P84-2 **Unveiling Anti-Hepatocellular carcinoma Potential of Withaferin A:Insights from Multi-Pronged Network Pharmacology study**  
 Saumya K Patel (School of Science, Gujarat University)

P84-3 **Vanillin: A Natural Plant-derived Compounds Against Cisplatin-Induced Muscle Oxidative Damage**  
 Ko Chieh Huang (School of Nutrition and Health Sciences, Taipei Medical University)

P84-4 **EGCG attenuates cancer-induced muscle atrophy in C2C12 myotubes**  
 Hsin-hua Li (National Taiwan University of Sport)

P84-5 **演題取下**

P84-6 **Population-based variability of PTM-impacted variants in DNA repair pathways**  
 Yu-han Huang (Institute of Molecular and Genomic Medicine, National Health Research Institute)

P84-7 **Awareness of Comprehensive Genomic Profiling and AYA Cancer Support among Healthcare Professionals in Osaka, Japan**  
 Tsutomu Nisida (Toyonaka Municipal Hospital)  
**豊能医療圏におけるがんゲノム医療の均てん化に向けて現状および課題を把握するためのアンケート調査研究**  
 西田 勉 (市立豊中病院)

P84-8 **An integrative multi-omics identifies the cholesterol biosynthesis-related protein as a key target for glioma stem cells**  
 Orasa Panawan (Khon Kaen University)

P84-9 **Development of a Pathologist Scoring Method to Determine Inflamed, Excluded or Desert Immune Phenotype in Carcinoma**  
**Encore**  
 Pierre Gontard (CellCarta NV)

P84-10 **Development of new tumor suppressor p53 pathway-activating cancer therapeutics**  
 Kohichi Kawahara (Department of Molecular Oncology, Graduate School of Medical and Dental Science, Kagoshima University)  
**がん抑制 p53 経路を活性化する新たな抗腫瘍機構を利用した新規がん治療薬の開発**  
 河原 康一 (鹿児島大学大学院医歯学総合研究科分子腫瘍学分野)

13:05-13:50 Poster Session 85

<b>P85</b>	<b>Breast Cancer 7 (Perioperative 3)</b> 乳腺 7 (周術期 3)
P85-1	演題取下
P85-2	<b>Nationwide Study on Breast Cancer Prevalence and Associated Risk Factors in Indonesia</b> Nadyatul Husna (Universitas Andalas, dr. Reksodiwiryo Military Hospital Padang)
P85-3	演題取下
P85-4	<b>Real world usage of pegfilgrastim on-body injector for breast cancer patients: a retrospective, single-institution study</b> Yuhei Yamaguchi (Department of Breast Medical Oncology, Breast Center, The Cancer Institute Hospital of JFCR, Japanese Foundation for Cancer Research) <b>乳癌患者に対するペグフィルグラスチム自動投与デバイス使用に関する単施設後方視的検討</b> 山口 祐平 (がん研究会有明病院 乳腺センター・乳腺内科)
P85-5	<b>Efficacy of Ribociclib Hormone Receptor-positive, HER 2-negative Breast Cancer Patients: A Meta-Analysis</b> Azzahra M Noersamsjah (Faculty of Medicine, Pelita Harapan University)
P85-6	演題取下
P85-7	<b>Consideration of the necessity of chemotherapy based on the experience of using the Oncotype DX. at our hospital</b> Sae Fujioka (Osaka Saiseikai Nakatsu Hospital) <b>当院におけるオンコタイプ DX 乳がん再発スコア<sup>®</sup> 検査の使用経験からみた化学療法要否の考察</b> 藤岡 沙江 (大阪府済生会中津病院)

13:05-13:50 Poster Session 86

<b>P86</b>	<b>Breast Cancer 8 (Metastatic Breast Cancer 1)</b> 乳腺 8 (転移性 1)
P86-1	<b>Comprehensive Review of Combination Therapy with Neratinib and Trastuzumab in HER2-Positive Breast Cancer Management</b> Ryan C Harliman (Faculty of Medicine, University of Pelita Harapan)
P86-2	<b>A review of our experience with trastuzumab deruxtecan in our hospital</b> Tomoko Itagaki (Clinical Oncology Breast Surgery) <b>当院におけるトラスツズマブデルクスステカン使用経験の検討</b> 板垣 友子 (JA 広島総合病院)
P86-3	<b>Real-world HER2-positive unresectable or metastatic breast cancer treatment patterns and outcomes in China</b> Wang Shusen (Department of Medical Oncology, Sun Yat-sen University Cancer Center)
P86-4	<b>Five-Year Survival in Locally Advanced and Advanced Breast Cancer: Full-Dose vs. Sandwich Neoadjuvant Chemotherapy</b> Farah Mardiyah (Research Assistant, Oncology Surgery Division, Department of Surgery, Arifin Achmad General Hospital)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Poster Experts

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P86-5	<b>演題取下</b>
P86-6	<b>演題取下</b>
P86-7	<b>Anti-metastatic Activity of Clitoria Ternatea Leaf Extract Through The Upregulation of E-cadherin: In Vitro Study</b> Azzahra Asyisyifa (Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada)
P86-8	<b>Capivasertib indications in metastatic breast cancer from comprehensive genomic profiling at Kyoto University Hospital</b> Chiaki Matsui (Department of Clinical Oncology, Kyoto University Hospital) <b>当院でがんゲノム検査を実施した乳癌症例におけるカピバセルチブの適応</b> 松井 千亜希 (京都大学医学部附属病院腫瘍内科)
13:05-13:50 Poster Session 87	
<b>P87</b>	<b>Breast Cancer 9 (Metastatic Breast Canc 2)</b> 乳腺 9 (転移性 2)
P87-1	<b>FIRST LINE RIBOCICLIB COMBINED WITH AROMATSE INHIBITOR IN METASTATIC HORMONE POSITIVE BREAST CANCER IN VIETNAM</b> Hoa T Nguyen (Vietnam National Cancer Hospital)
P87-2	<b>Changes in administration methods to continue treatment of HR+/HER2- MBC with the CDK4/6 inhibitor palbociclib</b> Makiko Go (Department of Pharmacy, Ogaki Municipal Hospital) <b>ホルモン受容体陽性 HER2 陰性転移・再発乳がんに対するパルボシクリブ (CDK4/6 阻害薬) の治療継続に向けた投与方法の工夫</b> 郷 真貴子 (大垣市民病院 薬剤部)
P87-3	<b>Withdrawn</b>
P87-4	<b>Breast cancer of the very elderly women and primary hormone therapy</b> Toshiro Yahara (Nagasaki prefecture iki hospital) <b>高齢者乳癌と 1 次ホルモン療法の経過について</b> 矢原 敏郎 (長崎県壱岐病院)
P87-5	<b>Treatment Outcome of Chemolmmunotherapy in Metastatic Breast Cancer Transforming from Luminal to Triple-Negative Subtype</b> Masayuki Miyata (Department of Medical Oncology, Kindai University Faculty of Medicine) <b>トリプルネガティブにサブタイプ変化した転移再発乳癌における免疫チェックポイント阻害薬併用化学療法の治療効果の検討</b> 宮田 将行 (近畿大学病院)
P87-6	<b>Five years Overall survival (OS) from Breast Cancer in tertiary hospitals in Bangladesh: TNBC was the leading variety</b> Abdullah Al M Khan (Shaheed Suhrawardy Medical College)
P87-7	<b>Treatment Outcome of Unresectable Advanced or Recurrent Triple-Negative Breast Cancer at our hospital</b> Satoru Takeji (Department of Medical Oncology, Hikone Municipal Hospital) <b>当院における切除不能進行・再発トリプルネガティブ乳癌の治療成績</b> 竹治 智 (彦根市立病院 腫瘍内科)

P88

Cross-sectional Program 6  
臓器横断プログラム 6

- P88-1 Ischemic stroke in patients with unresectable pancreatic and gastric cancer**  
Kohei Oka (Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine)  
**切除不能膵癌・胃癌に合併する脳梗塞**  
岡 浩平 (京都府立医科大学 消化器内科)
- P88-2 A retrospective analysis of Trousseau's syndrome**  
Masanori Takehara (Gastroenterology, Tokushima Red Cross Hospital)  
**当院におけるトルソー症候群の後方視的検討**  
武原 正典 (徳島赤十字病院)
- P88-3 Chinese Herbal Medicines prolong Blood Coagulation may Increase Bleeding Risks**  
Chun-kwok Cheng (Tung Wah College)
- P88-4 Prevalence of deep venous thrombosis in patients with head and neck cancer: an analysis from the PROVE-emboli study**  
Taku Nose (Department of Medical Oncology/Hematology, Kobe University Hospital)  
**進行・再発または転移の頭頸部癌未治療例の下肢静脈血栓症の有病率に関する報告 ( subgroup analysis from the PROVE-emboli study)**  
能勢 拓 (神戸大学医学部附属病院 腫瘍・血液内科)
- P88-5 Osteoporosis Risk in Colorectal Cancer Chemotherapy: A Retrospective Study Using CT-Based Screening**  
Sena Tsukamoto (Department of Medical Oncology and Chemotherapy, Takamatsu Red Cross Hospital)  
**大腸癌薬物療法に伴う骨粗鬆症リスクの実態解明-CTを用いた後方視的検討**  
塚本 汐奈 (高松赤十字病院 腫瘍内科)
- P88-6 The effect of Romosozumab on cancer treatment-induced bone loss in postmenopausal breast cancer patients**  
Shohei Tsujino (Department of orthopaedic surgery, Saitama prefectural cancer center)  
**難治性癌治療関連骨減少を有する乳がん患者におけるロモソズマブの骨密度改善効果と腫瘍学的安全性**  
辻野 昭平 (埼玉県立がんセンター整形外科)
- P88-7 The current issues and countermeasures of HBV surveillance for the cases with chemotherapy in our institute**  
Yuichiro Inagaki (Department of Oncology, Anjo Kosei Hospital)  
**HBV 既感染症例における薬物療法時のHBV サーベイランスの現状と課題**  
稲垣 裕一郎 (Anjo Kosei Hospital)
- P88-8 Analysis of risk factors for drug-induced lung injury in patients receiving trastuzumab-deruxtecan (T-DXd)**  
Yuka Kobayashi (Nagaoka Chuo General Hospital)  
**トラスツズマブ・デルクステカン (T-DXd) 投与症例の薬剤性肺障害合併に関する危険因子の検討**  
小林 由夏 (長岡中央総合病院)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P88-9 **Evaluation of Cardiotoxicity during Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer without Cardiotoxic Risk**  
 Akira Tsunoda (Department of Medical Oncology, Mie University Hospital)  
**心毒性リスクがないHER2陽性早期乳癌における術後トラスツズマブ療法中の心毒性：前向き観察研究**  
 角田 瑛 (三重大学医学部附属病院 腫瘍内科)

13:05-13:50 Poster Session 89

**P89** Cross-sectional Program 7  
 臓器横断プログラム7

P89-1 **Distinguishing axillary lymphadenopathy after COVID-19 vaccination from malignant lymphadenopathy**  
 Shintaro Yamanaka (Department of Clinical Oncology, Ehime University School of Medicine)  
**COVID-19 ワクチン接種後のリンパ節腫大とがん転移を鑑別するための後方視的検討**  
 山中 伸太郎 (愛媛大学医学部臨床腫瘍学講座)

P89-2 **Safety of CRISPR/Cas9 Modified Adoptive Cell Therapy in the Treatment of Cancer: A Systematic Review**  
 Michelle Vania (Faculty of Medicine, Pelita Harapan University)

P89-3 **Trends over time and regional differences in the prevalence of Microsatellite Instability (MSI) tests in Japan**  
 Masahiro Iwasaku (Kyoto Prefectural University of Medicine, Respiratory medicine)  
**マイクロサテライト不安定性 (MSI) 検査の検査数推移と内訳、地域差の検討**  
 岩破 将博 (京都府立医科大学大学院医学研究科 呼吸器内科)

P89-4 **Withdrawn**

P89-5 **Breast cancer susceptibility genotypes in the indigenous and understudied population of the Far North (Sakha)**  
 Aleksei Molokov (Tomsk Cancer Research Institute)

P89-6 **Evaluating the Effectiveness of a Health Intervention on Carcinogen Awareness Among Women in South India**  
 Deepika Yadav (Department of Community Medicine, JSS Medical College, JSS Academy of Higher Education and Research)

P89-7 **CTHist-Net: Accurate Multi-class Colorectal Tissue Identification in Histopathology Images by Attention-guided Network**  
 Tripti Singh (Department of Computer Engineering and Mathematics, Universitat Rovira i Virgili, Tarragona, Spain)

P89-8 **Sleep quality among Iraqi patients with cancer: A cross-sectional study**  
 Ghazwan Alhashem (AlSafwa University College)

P89-9 **Sexual behaviors and cancer risk: evidence from cross-sectional and prospective analyses in the UK population**  
**Encore**  
 Yao Song (West China Hospital, Sichuan University)

P90

Clinical Trial Facilitation Program 1  
臨床試験推進プログラム 1

- P90-1 **A Questionnaire Survey on the Utility of CyberOncology®: Insights from the PROCEED Study (WJOG15922G)**  
Mitsuhiro Furuta (Division of Gastroenterology, Kanagawa Cancer Center)  
**PROCEED 試験 (CyberOncology®) での CyberOncology® の利便性に関するアンケート調査**  
古田 光寛 (神奈川県立がんセンター消化器内科)
- P90-2 **Questionnaire Survey on Research Support for Practical Research for Innovative Cancer Control Management Office (PRIMO)**  
Yoshiyuki Sano (Practical Research for Innovative Cancer Control Management Office (PRIMO), National Cancer Center)  
**革新的がん研究支援室 (PRIMO) の研究支援活動に関するアンケート調査 (PRIMO コンサルテーション・技術支援スキーム)**  
佐野 慶行 (国立がん研究センター 革新的がん研究支援室 (PRIMO))
- P90-3 **Development of a Screening System for Clinical Trial Candidates**  
Ayako Yokomizo (Department of Early Clinical Development, Kyoto University Graduate School of Medicine)  
**臨床試験候補者スクリーニングシステムの構築**  
横溝 綾子 (京都大学大学院医学研究科 早期医療開発学)
- P90-4 **Utilization Survey on Research Support for “Cancer Treatment Development Chart” by PRIMO**  
Sachie Ishibashi (Practical Research for Innovative Cancer Control Management Office (PRIMO), National Cancer Center)  
**革新的がん研究支援室の治療開発マップに関する利活用調査**  
石橋 幸江 (国立がん研究センター 革新的がん研究支援室 (PRIMO))
- P90-5 **Project Orbis, international collaboration in antineoplastic drugs review, could mitigate risk of “drug lag/loss”**  
Yuki Miyatake (Japan Regulatory Affairs, Eli Lilly Japan K.K.)  
**抗悪性腫瘍薬を国際協同審査する枠組み Project Orbis は、革新的医薬品の “ドラッグラグ・ロス問題” の解消に貢献する**  
宮武 祐樹 (日本イーライリリー株式会社)
- P90-6 **Cost-effectiveness analysis of Fosnetupitant, an NK1 Receptor Antagonist, Compared to Fosaprepitant and Aprepitant**  
Hiroshi Inano (Department of Pharmacy)  
**NK1 受容体拮抗薬ホスネツピタントのホスアプレピタント及びアプレピタントに対する費用対効果分析**  
稲野 寛 (北里大学病院)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Room 1  
Room 2  
Room 3  
Room 4  
Room 5  
Room 6  
Room 7  
Room 8  
Room 9  
Room 10  
Room 11  
Room 12  
Room 13  
Room 14  
Meet the Experts  
Poster

P90-7 演題取下

13:05-13:50 Poster Session 91

**P91** Clinical Trial Facilitation Program 2  
臨床試験推進プログラム 2

P91-1 **Role of Cancer Genome Medicine Coordinators (CGMC) in Promoting Clinical Trials**

Masumi Yamazaki (Department of Genome Medicine)

**臨床試験推進におけるがんゲノム医療コーディネーター (CGMC) の役割**

山崎 真澄 (がん研究会有明病院)

P91-2 **A comparative analysis of clinical trials in low and high incidences of cancer in JCOG trials**

Yusuke Sano (National Cancer Center Hospital)

**JCOG 試験における罹患率の低いがん領域と罹患率の高いがん領域の臨床試験の比較**

佐野 裕亮 (国立がん研究センター中央病院)

P91-3 **Evaluation of expert panel simplification in Kyoto University Hospital**

Masahiro Yoshioka (Department of Clinical Oncology, Kyoto University Hospital)

**当院におけるエキスパートパネル簡略化の検討**

吉岡 正博 (京都大学医学部附属病院 腫瘍内科)

P91-4 **Investigation of Methods to Extract Patients with Febrile Neutropenia for Hematologic Malignancies from DPC Data**

Kazuhiro Ishikawa (International University of Health and Welfare)

**DPC データから血液悪性腫瘍化学療法中の発熱性好中球減少症患者を抽出する方法の検討**

石川 和宏 (国際医療福祉大学)

P91-5 **The New Role Model for Medical Oncologists Specializing in Early Clinical Development**

Takeshi Sawada (Kyoto University Hospital)

**早期医療開発を専門とする腫瘍内科医：新たなロールモデルについて**

澤田 武志 (京都大学医学部附属病院)

P91-6 **Establishment of a Pharmacometrics Team: Enhancing Drug Development through Quantitative Analysis**

Yutaka Shimazu (Department of Early Clinical Development, Graduate School of Medicine, Kyoto University/ Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy, Kyoto University Hospital)

**ファーマコメトリクス・チームの設立：定量分析による医薬品開発の強化**

島津 裕 (京都大学医学部附属病院早期医療開発科, 先端医療研究開発機構 次世代医療・iPS 細胞治療研究センター)

P91-7 **Machine Learning (ML)-Enabled Automation for High-Throughput Data Processing in Flow Cytometry**

**Encore**

Anna L Kamysheva (BostonGene, Corp.)



P92

Clinical Trial Facilitation Program 3  
臨床試験推進プログラム 3

P92-1

Encore

**A phase III randomized trial of surgery and HIPEC in platinum-resistant recurrent ovarian cancer KOV-HIPEC-02**

Ji Hyun C Kim (National Cancer Center Korea)

P92-2

Encore

**A phase III randomized trial in primary stage III-IV ovarian cancer after interval cytoreductive surgery: KOV-HIPEC-04**

Ji Hyun C Kim (Gynecologic Cancer Center, National Cancer Center)

P92-3

Encore

**Phase 1b study evaluating efficacy and safety of ABBV-400 in select advanced solid tumor indications**

Shigehiro Koganemaru (National Cancer Center Hospital East)

**特定の進行性固形がんを対象とした ABBV-400 の有効性および安全性を評価する第 1b 相試験**

Shigehiro Koganemaru (National Cancer Center Hospital East)

P92-4

Encore

**Valemetostat Plus Trastuzumab Deruxtecan (T-DXd) or Datopotamab Deruxtecan (Dato-DXd) in Patients With Solid Tumors**

Yoichi Naito (Department of General Internal Medicine, National Cancer Center Hospital East)

**固形癌患者を対象としたバレメトスタットシル酸塩と DXd ADC(T-DXd または Dato-DXd) の併用療法を検討する多施設共同非盲検第 1b 相試験**

内藤 陽一 (国立がん研究センター東病院)

P92-5

**Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing(A-TRAIN trial): Nasopharyngeal Carcinoma cohort**

Yuki Kojima (National Cancer Center Hospital)

**Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing(A-TRAIN trial): Nasopharyngeal Carcinoma cohort**

小島 勇貴 (国立がん研究センター中央病院)

P92-6

**The impact of puncture needle type on the performance of blood sampling in phase I trials -A retrospective study**

Junko Murakami (Nursing Division)

**第 I 相試験の採血用ルート (PK ルート) における穿刺針 (機能なし穿刺針と血液曝露防止弁機能付き穿刺針) 選択による穿刺関連イベントおよび穿刺回数の方視的検討**

村上 順子 (国立がん研究センター中央病院)

P92-7

**Safety trial of antibiotic fecal microbiota transplantation for esophageal and gastric cancer patients treated with ICIs**

Yuri Yoshinami (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)

**免疫チェックポイント阻害薬を導入する食道がん・胃がん患者に対する抗菌薬併用腸内細菌叢移植療法の安全性試験**

善浪 佑理 (国立がん研究センター中央病院 消化管内科)

P93

Clinical Trial Facilitation Program 4  
臨床試験推進プログラム 4

- P93-1 Efficacy of Trastuzumab Deruxtecan and Biomarker Changes in HER2-Positive Gastric Cancer: EN-MARK Study Protocol**  
Akira Ooki (Cancer Institute Hospital of the Japanese Foundation for Cancer Research)  
**進行 / 再発 HER2 陽性胃がん患者を対象とした三次治療における T-DXd の有効性の評価、及び一次治療後のバイオマーカーを探索的に検討する多施設共同前向き研究 (EN-MARK)**  
大木 暁 (がん研究会有明病院)
- P93-2 Randomized Phase II Study of Fixed Dose of Zolbetuximab for CLDN18.2-positive mGC/GEJC (GENTLE-Z)**  
Momoka Furuoka (National Cancer Center Hospital East)  
**CLDN18.2 陽性胃癌 / 食道胃接合部癌に対するゾルベツキシマブの固定用量のランダム化第 II 相試験 (GENTLE-Z)**  
古岡 桃果 (国立がん研究センター東病院)
- P93-3 A phase 2 study of mFOLFOX6 plus nivolumab for untreated advanced esophageal squamous-cell cancer: FLONTALE trial**  
**Encore**  
Yohei Kubota (Clinical Oncology)  
**未治療の切除不能または再発食道癌に対する mFOLFOX6+ ニボルマブ療法の第 II 相試験**  
久保田 洋平 (聖マリアンナ医科大学病院)
- P93-4 First-line Bemarituzumab + SOX + Nivolumab for Advanced G/GEJC with FGFR2b Overexpression: FORTITUDE-103 Phase 2 Design**  
Shunsuke Kagawa (Okayama University)  
**FGFR2b 過剰発現性進行胃癌及び食道胃接合部癌に対するベマリツズマブ、SOX 及びニボルマブを併用した一次治療: 第 2 相 FORTITUDE-103 試験デザイン**  
Shunsuke Kagawa (Okayama University)
- P93-5 IDEate-Lung02: Phase 3 study of ifinatamab deruxtecan (I-DXd) in relapsed small cell lung cancer (SCLC)**  
**Encore**  
Hidetoshi Hayashi (Department of Medical Oncology, Kindai University Faculty of Medicine)  
**再発小細胞肺癌患者を対象とした I-DXd の第 3 相試験 (IDEate-Lung02 試験)**  
林 秀敏 (近畿大学医学部)
- P93-6 ifinatamab deruxtecan + atezolizumab ± carboplatin as first line therapy for extensive stage small cell lung cancer**  
**Encore**  
Hidetoshi Hayashi (Department of Medical Oncology, Kindai University Faculty of Medicine)  
**ES-SCLC の一次治療としてカルボプラチン併用下又は非併用下で I-DXd をアテゾリズマブと併用投与する第 1b/2 相試験 (IDEate-Lung03 試験)**  
林 秀敏 (近畿大学医学部)
- P93-7 Valemetostat Plus Pembrolizumab in 1st-line NSCLC Without Actionable Genomic Alterations Expressing PD-L1 With TPS  $\geq$  50%**  
Noboru Yamamoto (National Cancer Center Hospital)  
**PD-L1 高発現の進行・再発非小細胞肺癌を対象としたバレメトスタットとペムブロリズマブの併用第 1b/2 相試験**  
山本 昇 (国立がん研究センター中央病院)

- P94-1** **The determinant factors which prevent the patients from receiving second-line chemotherapy in ES-SCLC**  
Ryohiko Ozaki (Respiratory Medicine and Rheumatology)  
**進展型小細胞肺癌における二次化学療法を妨げる因子の検討**  
尾崎 領彦 (徳島大学病院)
- P94-2** **The efficacy of chemo-immunotherapy on the regulation of distant metastasis in extensive-stage small-cell lung cancer**  
Rikako Matsumoto (Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University)  
**進展型小細胞肺癌における化学免疫療法の遠隔転移制御効果に関する後方視的検討**  
松本 利加子 (徳島大学大学院医歯薬学研究部 呼吸器・膠原病内科学分野)
- P94-3** **Region or Institutional Type and Survival Outcomes of ED-SCLC Patients Treated with Chemotherapy in Clinical Practice**  
Tomoya Fukui (Shonan Kamakura General Hospital)  
**実臨床においてがん薬物療法を受けた進展型小細胞肺癌患者の地域あるいは施設タイプと生存成績**  
福井 朋也 (湘南鎌倉総合病院)
- P94-4** **Impact of Brain Metastasis Assessment Modality on Outcomes of Prophylactic Cranial Irradiation in LD-SCLC**  
Mikako Nakamura (Department of Thoracic Oncology)  
**限局型肺小細胞肺癌における脳転移の評価方法が予防的全脳照射の効果に与える影響に関する検討**  
仲村 実花子 (国立がん研究センター中央病院 呼吸器内科)
- P94-5** **Efficacy and safety of chemoradiotherapy in elderly patients with limited- disease small cell lung cancer**  
Suguru Matsuda (Division of Thoracic Oncology, Shizuoka Cancer Center)  
**75歳以上の限局型小細胞肺癌に対する化学放射線逐次併用療法の有効性および安全性を評価した後方視的検討**  
松田 賢 (静岡県立静岡がんセンター呼吸器内科)
- P94-6** **Analysis of clinical characteristics in long-term survivors of extensive-stage small cell lung cancer**  
Yuki Hatakeyama (Department of Respiratory Medicine, Hokkaido University Hospital)  
**進展型小細胞肺癌長期生存例の検討**  
畠山 西季 (北海道大学病院 呼吸器内科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P94-7 **Characteristics of comprehensive genome profiling and RNA sequencing in EGFR-mutant lung cancer with SCLC transformation**  
 Shinsuke Ogusu (Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University)

**EGFR 遺伝子変異陽性肺癌の小細胞癌転化を来たした症例におけるがんゲノム解析および RNA シークエンスの特徴**  
 小楠 真典 (佐賀大学医学部附属病院)

P94-8 **Can inflammation and nutritional markers predict the response of chemotherapy in patients with SCLC?**  
 Ichizo Kobayashi (Faculty of Medicine, Tohoku Medical and Pharmaceutical University)

**炎症・栄養マーカーは小細胞肺癌患者において薬物療法の効果を予測できるか?**  
 小林 一蔵 (東北医科大学 医学部 医学科)

P94-9 **Investigation of ICI treatment for advanced small cell lung cancer in our hospital**  
 Susumu Noguchi (Department of Respiratory Medicine)

**当院における進展型小細胞肺癌に対する ICI 治療の検討**  
 野口 進 (滋賀県立総合病院)

13:05-13:50 Poster Session 95

**p95 Lung Cancer / Thoracic Cancer 11 (Case Report 2)**  
 呼吸器 11 (ケースレポート 2)

P95-1 **First Case Report of Thoracic Inflammatory Myofibroblastic Tumor Harboring Complex and Rare ALK Fusions with Loratinib**  
 Libo Tang (School of Medicine, South China University of Technology, Guangzhou, Guangdong 510080, China)

P95-2 **Pembrolizumab in Microsatellite-Instability-High Large Cell Neuroendocrine Carcinoma of the Lung: a case report**  
 Toshihiro Masuda (Respiratory medicine)  
**高頻度マイクロサテライト不安定性を有する肺大細胞神経内分泌腫瘍に Pembrolizumab を投与した 1 例**  
 増田 寿寛 (静岡市立静岡病院)

P95-3 **A case of HER2 positivity detected by gene panel testing after the initiation of fourth-line therapy**  
 Naoki Miyamoto (Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Biosciences, The University of Tokushima)  
**肺癌術後再発に対する 4 次治療開始後の遺伝子パネル検査で HER2 陽性が判明した 1 例**  
 宮本 直輝 (徳島大学病院胸部・内分泌・腫瘍外科学)

P95-4 **Comprehensive Cancer Genome Profiling Examination in Advanced/Recurrent Lung Cancer**  
 Fumihiko Hirai (Department of surgery, Saiseikai Fukuoka General Hospital)  
**包括的がんゲノムプロファイリング検査を実施した進行期 / 再発肺癌の検討**  
 平井 文彦 (福岡県済生会福岡総合病院 外科)

- P95-5 **Nivolumab and ipilimumab used to malignant pleural mesothelioma with constitutional jaundice, and jaundice prolonged**  
Koichi Fujii (Southern TOHOKU General Hospital)  
**体質性黄疸を有する悪性胸膜中皮腫に nivolumab と ipilimumab を投与し、黄疸が遷延している症例**  
藤生 浩一 (総合南東北病院)
- P95-6 **A case of anti-Hu positive paraneoplastic limbic encephalitis with SCLC that achieved long effect by chemoradiotherapy**  
Toshiyuki Kita (Department of Respiratory Medicine, NHO Kanazawa Medical Center)  
**化学放射線療法により長期間の奏効を得た抗 Hu 抗体陽性傍腫瘍性辺縁系脳炎小合併細胞肺癌の 1 例**  
北 俊之 (NHO Kanazawa Medical Center)
- P95-7 **Autopsy case of primary tracheal cancer developing airflow obstruction**  
Naoki Shiota (Chugoku Rosai Hospital)  
**気道狭窄を来した原発性気管癌の一部検例**  
塩田 直樹 (中国労災病院)

13:05-13:50 Poster Session 96

**P96** Lung Cancer / Thoracic Cancer 12 (Non-Small Cell Lung Cancer 8 (Chemotherapy))  
呼吸器 12 (非小細胞肺癌 8 (化学療法))

- P96-1 **Efficacy of nanoparticle albumin-bound paclitaxel following immune checkpoint inhibitor**  
Koki Nakashima (University of Fukui Hospital)  
**免疫チェックポイント阻害薬投与後のナブパクリタキセルの有用性**  
中嶋 康貴 (福井大学医学部付属病院)
- P96-2 **Addition of ICI to platinum retreatment for recurrent NSCLC after perioperative chemo: a multicenter retrospective study**  
Toshiaki Takakura (Internal Medicine III, Wakayama Medical University)  
**周術期プラチナ療法投与歴のある非小細胞肺癌に対する再発後免疫チェックポイント阻害薬併用プラチナ療法再投与についての多施設後方視的研究**  
高倉 敏彰 (和歌山県立医科大学 内科学第3講座 (呼吸器内科・腫瘍内科))
- P96-3 **Days at home for patients with lung cancer treated with chemotherapy: A retrospective cohort study using Claims Data**  
Yuri Ogura (Department of Pulmonary Medicine)  
**化学療法を施行した肺癌患者の days at home——レセプトデータを用いた検討**  
小倉 由莉 (京都府立医科大学)
- P96-4 **Biomarkers of Docetaxel plus Ramucirumab in Non-Small Cell Lung Cancer: A Multicenter Observational Study**  
Shinnosuke Takemoto (Department of Respiratory Medicine, Nagasaki University Hospital)  
**非小細胞肺癌におけるドセタキセルとラムシルマブのバイオマーカーの検討: 多施設共同観察研究**  
竹本 真之輔 (長崎大学病院 呼吸器内科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

- P96-5 **The Efficacy of Docetaxel in Patients Treated with 1L Combination Carboplatin with Gemcitabine vs Paclitaxel in mNSCLC**  
Chalermchai Lertanansit (Surin hospital, Thailand)
- 
- P96-6 **Pembrolizumab vs Chemotherapy for Untreated Metastatic Non Small Cell Lung Cancer Patients: A Systematic Review**  
Sherryl K Tatawi (Faculty of Medicine, Pelita Harapan University, Indonesia)
- 
- P96-7 **Association of TTF-1 Expression and Efficacy of the KEYNOTE-189 Regimen in Lung Adenocarcinoma: A Retrospective Study**  
Yosuke Tamura (Osaka medical and pharmaceutical university hospital)  
**肺腺癌における TTF-1 発現と KEYNOTE-189 レジメンの有効性に関する後方視的検討**  
田村 洋輔 (大阪医科薬科大学病院)
- 
- P96-8 **Pooled efficacy and safety from 2 pivotal phase II trials of taletrectinib in patients with advanced ROS1+ NSCLC**  
Takashi Seto (NHO Kyushu Cancer Center)  
**ROS1 融合遺伝子陽性進行再発非小細胞肺癌患者を対象としたタレトレクチニブ統合解析 -2 つの第 II 相臨床試験から -**  
瀬戸 貴司 (九州がんセンター)
- 
- 13:05-13:50 Poster Session 97
- 
- P97** Lung Cancer / Thoracic Cancer 13 (Early Stage Non-Small Cell Lung Cancer9 / Perioperative Treatment)  
呼吸器 13 (非小細胞肺癌 9 (周術期))
- 
- P97-1 **Identify Prognosis Biomarkers within Dysregulated Pathways of Lung Adenocarcinoma**  
Ying-chieh Ko (Institute of Molecular and Genomic Medicine, National Health Research Institutes)
- 
- P97-2 **Impact of Antibiotic Use in Asymptomatic Incidental Indeterminate Pulmonary Nodules in the Post-COVID-19 Era**  
Long Jiang (Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine)
- 
- P97-3 **Efficacy and safety of adjuvant atezolizumab and osimertinib for non-small cell lung cancer at our hospital**  
Masahide Ota (Department of Cancer Genomics and Medical Oncology, Nara Medical University)  
**当院での非小細胞肺癌術後補助療法としての Atezolizumab・Osimertinib の有効性と安全性の検討**  
大田 正秀 (奈良県立医科大学 がんゲノム・腫瘍内科学講座)
- 
- P97-4 **The Role of PRKCSH in Modulating IRE1 Signaling and ER Stress Induced Cell Death in Lung Cancer**  
Xiyuan Guo (Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University)
- 
- P97-5 **In Silico Test of Phytochemical Compounds from Tapak liman (Elephantopus Scaber L) in Lung Cancer Treatment Efforts**  
Decenly Decenly (Universitas Palangka Raya)

- P97-6 **A summary of 6 cases who received neoadjuvant chemotherapy with Checkmate816 regimen and two instructive case reports**  
 Soichiro Minami (Pulmonary medicine, Sendai Kosei Hospital)  
**Checkmate816 レジメンによるネオアジュバント化学療法を受けた 6 例要約と 2 症例報告**  
 南 宗一郎 (仙台厚生病院呼吸器内科)
- P97-7 **Correlation of Genetic Mutation Results and Postoperative EGFR TKI Adjuvant Therapy in Lung Adenocarcinoma Surgery Cases**  
 Takashi Inoue (Dokkyo Medical University)  
**肺腺癌手術症例における遺伝子変異検査結果と、術後 EGFR TKI による補助療法との関係についての検討**  
 井上 尚 (獨協医科大学)
- P97-8 **A retrospective investigation on postoperative adjuvant chemotherapy using immune checkpoint inhibitors**  
 Tetsuro Kondo (Kanagawa Cancer Center, Department of Thoracic Oncology)  
**抗 PD-L1 抗体を用いた術後補助化学療法例に関する検討**  
 近藤 哲郎 (神奈川県立がんセンター 呼吸器内科)
- P97-9 **Monitoring and clinical significance of peripheral PD-1-positive lymphocytes in patients with non-small-cell lung cancer**  
 Koji Teramoto (Department of Medical Oncology, Shiga University of Medical Science)  
**非小細胞肺癌における末梢血中の PD-1 陽性リンパ球のモニタリングおよび臨床的特徴について**  
 寺本 晃治 (滋賀医科大学 臨床腫瘍学講座 (腫瘍内科))

13:05-13:50 Poster Session 98

- p98** Hematologic Malignancies 7 (Myeloma)  
 血液 7 (骨髄腫)
- P98-1 **Ocular events in patients treated with belantamab mafodotin, pomalidomide and dexamethasone (BPd) in the DREAMM-8 study**  
**Encore**  
 Kazuhito Suzuki (Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine)
- P98-2 **Ocular events in patients treated with belantamab mafodotin, bortezomib and dexamethasone (BVd) in the DREAMM-7 study**  
**Encore**  
 Vania Hungria (Clinica São Germano)
- P98-3 **Efficacy and Safety of Daratumumab Quadruplet vs. Triplet Therapy in Newly Diagnosed Multiple Myeloma: A Meta-Analysis**  
**Encore**  
 Saad Nasir (Aga Khan University Hospital)
- P98-4 **Analysis of the correlation between body weight and efficacy and incidence of side effects of daratumumab SC**  
 Yusuke Nakamura (Department of Pharmacy, Sapporo Hokuyu Hospital)  
**ダラツムマブ皮下投与において体重と有効性および副作用発現率の相関性の解析**  
 中村 雄亮 (札幌北楡病院 薬剤部)

**P98-5 Optimal utilization of Carfilzomib-based regimens for relapsed/refractory multiple myeloma in real-world practice**

Kotaro Miyao (Department Hematology and Oncology, Anjo Kosei Hospital)  
**実臨床における再発難治多発性骨髄腫に対するカルフィルゾミブに基づくレジメンの至適活用の検討**  
 宮尾 康太郎 (安城更生病院 血液・腫瘍内科)

**P98-6 The Outcomes of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis**

Made Sindy Astri Pratiwi (Faculty of Medicine, Udayana University)

13:05-13:50 Poster Session 99

**P99 Hematologic Malignancies 8 (Other Hematologic Diseases)**  
 血液 8 (その他血液疾患)

**P99-1 Evaluation of Shifts in Acquired Immunity after hematopoietic Stem Cell Transplantation through Repertoire Analysis**

Sakuya Matsumoto (Department of Oncology and Hematology, Kobe University Hospital)  
**レパトア解析を用いた造血幹細胞移植後の獲得免疫の変化の評価**  
 松本 咲耶 (神戸大学医学部附属病院 腫瘍・血液内科)

**P99-2 Phase 3 study of bomedemstat vs hydroxyurea in patients with essential thrombocythemia naive to cytoreductive therapy**

Yuka Sugimoto (Mie University Graduate School of Medicine)

**P99-3 A treatment with luspatercept for patients with low-risk myelodysplastic syndrome**

Naoki Hayase (hematology, Gifu Prefectural General Medical Center)  
**低リスク骨髄異形成症候群患者に対するルスパテルセプトによる治療**  
 早瀬 直輝 (Gifu Prefectural General Medical Center)

**P99-4 Delayed methotrexate Elimination: Six Cases of lymphoid malignancies After HD-MTX therapy**

Kazuki Hashimoto (Tohoku university graduate school of medicine)  
**高用量メトトレキサート投与後のメトトレキサート排泄遅延症例の検討**  
 橋本 和貴 (東北大学大学院医学系研究科)

**P99-5 Comparison in adverse events between first- and second-generation BTK inhibitors : a real-world retrospective analysis**

Ao Ito (Faculty of Pharmacy, Meijo University)  
**第一世代、第二世代 BTK 阻害剤の実臨床における有害事象比較：単施設後方視的検討**  
 伊藤 愛桜 (名城大学薬学部)

**P99-6 Rare hematological complications during immune checkpoint inhibitor therapy in our hospital**

Yasuhiko Harada (Hematology, Toyota Kosei Hospital)  
**免疫チェックポイント治療中に当院で認めた稀な血液学的合併症**  
 原田 靖彦 (豊田厚生病院 血液内科)

**P99-7 Withdrawn**



**P100** Hematologic Malignancies 9 (Case Report 3)  
 血液 9 (ケースレポート 3)

- P100-1** **Case report: Complete response to acalabrutinib maintenance following Mantle cell lymphoma ASCT**  
 Hai Yi (Institute of Hematology, Department of Hematology, People's Liberation Army The General Hospital of Western Theater Command, Sichuan Clinical Research Center for Hematological Disease, Branch of National Clinical Research Center for Hematological Disease, Chengdu, Sichuan, China)
- P100-2** **A case of successfully treated lymphoplasmacytic lymphoma complicated by tumor-associated immune thrombocytopenia**  
 Miina Nasukawa (Department of Hematology and Oncology, Tokai University School of Medicine)  
 治療が奏功した腫瘍関連免疫性血小板減少症を伴うリンパ形質細胞性リンパ腫の一例  
 名須川 美衣菜 (東海大学医学部内科学系血液・腫瘍内科)
- P100-3** **Relapsed and refractory diffuse large B-cell lymphoma treated with epcoritamab in our hospital**  
 Hideko Goto (Department of Hematology, Chuno Kosei Hospital)  
 当院における難治性 DLBCL に対するエプコリタマブの使用経験  
 後藤 英子 (中濃厚生病院)
- P100-4** **Primary bladder lymphoma with peri-vesical expansion - A case report and literature review of prognosis -**  
 Hideshige Seki (Department of Internal Medicine, Division of Hematology, Aichi Medical University)  
 静脈近傍への進展を呈する原発性膀胱リンパ腫 - 症例報告と特徴・予後の解析 -  
 關 栄茂 (愛知医科大学)
- P100-5** **Haematological Malignancies in Geriatric Patients**  
 Nur Imma Fatimah Harahap (Universitas Gadjah Mada (UGM))
- P100-6** **Metastatic Breast Cancer Following Remission of Acute Promyelocytic Leukemia: A Case Report**  
 Cristina G Domingo (Cancer Center, Mariano Marcos Memorial Hospital and Medical Center)
- P100-7** **A Case of Double Synchronous Primary Malignant Tumor DLBCL Lymphoma of the Ovary & Squamous Cell Carcinoma of the Cervix**  
 Ardi Ardian (Division of Hematology and Medical Oncology, Departement of Internal Medicine, Faculty of Medicine, Dr Ciptomangunkusumo Hospital, Universitas Indonesia)

**P101** Rare Cancer / Cancer of Unknown Primary 7 (Skin Cancer / Melanoma)  
 希少がん・原発不明がん 7 (皮膚癌・メラノーマ)

- P101-1 **C-Reactive Protein as a Prognostic Marker for Uveal Melanoma: A Meta-Analysis of Current Literatures**  
 Yoseph M Siahhaan (Department of Ophthalmology, Faculty of Medicine, Pelita Harapan University)
- P101-2 **Cemiplimab in the Treatment of Cutaneous Squamous Cell Carcinoma (cSCC): A Systematic Review and Meta-Analysis**  
 Ayu Irviani U Amalia (Pelita Harapan University)
- P101-3 **Cysteinyl leukotriene receptor 1 antagonists inhibit human melanoma migration by decreasing cathepsin B and RUNX levels**  
 Ratchanon Sukprasert (Faculty of Allied Health Sciences, Burapha University)
- P101-4 **Efficacy of Nivolumab plus Ipilimumab versus Monotherapy against Advanced Melanoma: A Systematic Review**  
 Cynthia Marcelly A Gunawan (Faculty of Medicine, Pelita Harapan University)
- P101-5 **Real-world anti-cancer therapy sequences and timing of CGP in 237 patients with advanced melanoma in Japan**  
 Takuro Noguchi (Department of Medical Oncology, Hokkaido University Graduate School of Medicine)  
**日本人進行悪性黒色腫 237 例の実臨床における抗がん薬使用と CGP タイミングに関する検討**  
 野口 卓郎 (Department of Medical Oncology, Hokkaido University Graduate School of Medicine)
- P101-6 **Current Status and Challenges in the Treatment of Mucosal Melanoma**  
 Hidenori Ojio (Department of Gastroenterological Surgery, Aichi Cancer Center Central Hospital)  
**粘膜メラノーマ治療の現状と課題**  
 小塩 英典 (愛知県がんセンター 消化器外科部)
- P101-7 **Immune Checkpoint Inhibitor-Induced Uveitis Managed Successfully with Topical Steroids in Anal Melanoma**  
 Ayaka Mimura (Department of General Internal Medicine 4, Kawasaki Medical School)  
**免疫チェックポイント阻害薬により発症したぶどう膜炎に対してステロイド局所投与が有効であった肛門管メラノーマ**  
 三村 彩香 (川崎医科大学 総合内科学 4)
- P101-8 **Efficacy and Safety of Tebentafusp in Metastatic Uveal Melanoma: A Systematic Review**  
 William S Atmaja (Pelita Harapan University, Faculty of Medicine)

**P102** Rare Cancer / Cancer of Unknown Primary 8 (Endocrine Cancer, Thyroid Cancer, Neuroendocrine Tumor)  
 希少がん・原発不明がん 8 (甲状腺腫瘍・神経内分泌腫瘍)

- P102-1** **Efficacy and Safety of Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE for Neuroendocrine Tumors**  
 Rika Saito (Department of Medical Oncology, Fukushima Medical University)  
**当院における神経内分泌腫瘍に対する 177Lu-DOTATATE を用いたペプチド受容体放射線核種療法の有効性と安全性**  
 斎藤 里佳 (福島県立医科大学 腫瘍内科学講座)
- P102-2** **Thyroid Cancer Cases in Fukushima: Merging Analysis of the Fukushima Health Management Survey and Cancer Registry**  
 Reiko Kimura (Department of Medical Oncology, Fukushima Medical University)  
**福島県内の甲状腺がん症例に関する検討 - 福島県「県民健康調査」とがん登録の突合 -**  
 木村 礼子 (福島県立医科大学 腫瘍内科学講座)
- P102-3** **Effect of Kampo medicines in supportive care for the multikinase inhibitor lenvatinib therapy of advanced thyroid cancer**  
 Akifumi Suzuki (Surgery)  
**進行甲状腺癌に対するマルチキナーゼ阻害剤レンバチニブ治療における支持療法での漢方薬の効果**  
 鈴木 章史 (伊藤病院 外科)
- P102-4** **Current Status of PRRT Treatment at Okayama University Hospital**  
 Shigeru Horiguchi (Okayama University Hospital)  
**岡山大学病院における PRRT 治療の現状について**  
 堀口 繁 (岡山大学病院)
- P102-5** **Efficacy of 177Lu-DOTATATE for NETs in Hiroshima University Hospital**  
 Takatsune Hosoya (Department of Respiratory Medicine, Hiroshima University Hospital)  
**当院における NET に対する 177Lu-DOTATATE の有効性の検討**  
 細谷 堯永 (広島大学病院 呼吸器内科)
- P102-6** **A case series of advanced neuroendocrine tumor treated with 177 Lutetium-peptide receptor radionuclide therapy**  
 Tomoaki Shirakawa (Department of Medical Oncology, Tohoku University Hospital)  
**当院における神経内分泌腫瘍に対するペプチド受容体放射性核種療法の有効性と安全性の検討**  
 白川 智章 (東北大学病院 腫瘍内科)
- P102-7** **Locally Advanced Rectal Neuroendocrine Carcinoma Treated with Conversion Chemotherapy of Cisplatin/Etoposide**  
 Kanako Yokomizo (Department of Medical Oncology, Kameda General Hospital)  
**Cisplatin/Etoposide による Conversion chemotherapy を施行した局所進行直腸 NEC の一例**  
 横溝 加奈子 (亀田総合病院 腫瘍内科)
- P102-8** **Unveiling Sunitinib: A Systematic Review of Its Impact on Managing Advanced Pheochromocytoma and Paraganglioma**  
 Hasti H Tolani (Faculty of Medicine, Pelita Harapan University)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P102-9 **Paranglioma of urinary bladder in a young female patient - A case report**  
 Shihyu Huang (Divisions of Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital)

13:05-13:50 Poster Session 103

**P103** Rare Cancer / Cancer of Unknown Primary 9 (Other 3)  
 希少がん・原発不明がん 9 (その他 3)

P103-1 **STUDY TO DETERMINE TREATMENT OUTCOMES OF GANGLIONEUROBLASTOMA IN PEDIATRIC CANCER PATIENTS AT AIC KIJABE HOSPITAL, KENYA**  
 Peres P Girisa (AIC Kijabe Hospital)

P103-2 **An Individualized Approach to Primary Mediastinal Germ Cell Tumor: A Case Report**  
 Russell Daniel C Barros (Chinese General Hospital and Medical Center)

P103-3 **High-risk choriocarcinoma: clinical practice with five regimens involving EMA-EP to a patient at an advanced stage**  
 Satoshi Hirakawa (Department of Supportive Care in Cancer, Seirei Hamamatsu General Hospital)  
**ハイリスク群の絨毛癌:EMA-EP療法を含む5つのレジメンで薬物療法を実施した治療経験**  
 平川 聡史 (Seirei Hamamatsu General Hospital)

P103-4 **A survey on the current state of rare cancer patients treated with chemotherapy at a university hospital**  
 Hidetoshi Sumimoto (Department of Medical Oncology, Shiga University of Medical Science)  
**大学病院で薬物療法を施行された希少癌患者の実態調査**  
 住本 秀敏 (滋賀医科大学臨床腫瘍学講座)

P103-5 **Clinicopathological of Human Kallikrein-Related Peptidase-6 (KLK6) Overexpression in Solid Cancers**  
 Putu Ari Shanti Dewi (Udayana University)

P103-6 **BLEOMYCIN INDUCED PNEUMONITIS TREATED WITH IMATINIB IN AN ADULT FEMALE DIAGNOSED WITH YOLK SAC TUMOR OF THE OVARY**  
 Julius Ray C Bautista (St. Luke's Medical Center Cancer Institute)

P103-7 **PAZOPANIB-ASSOCIATED TUMOR LYSIS SYNDROME IN METASTATIC CLEAR CELL RENAL CELL CARCINOMA: A CASE REPORT**  
 Athena Mae Ibon (CEBU SOUTH MEDICAL CENTER)

P103-8 **A case report of ifosfamide-related Fanconi syndrome which was discovered due to persistent lower limb pain**  
 Kentaro Sawada (Kushiro Rosai Hospital, Department of Medical Oncology)  
**持続する下肢痛を契機に指摘されたイホスファミド関連 Fanconi 症候群の 1 例**  
 澤田 憲太郎 (釧路労災病院 腫瘍内科)

- P103-9 **Advanced Gastroesophageal Adenocarcinoma Presenting with Erythroderma; Partially Responding to Pembrolizumab Monotherapy**  
 Saive Marie Jadraque (CEBU SOUTH MEDICAL CENTER)  
**最初に紅皮症を呈し、ペムブロリズマブ単剤療法に部分的に反応した進行性胃食道腺癌：症例報告**  
 Saive Marie Jadraque (CEBU SOUTH MEDICAL CENTER)

13:05-13:50 Poster Session 104

**P104** Multidisciplinary Team Program 6 (Oncology Nursing)  
 多職種連携プログラム 6 (看護)

- P104-1 **A survey of cryotherapy for peripheral neuropathy in gynecological cancer patients treated with TC therapy**  
 Maiko Matsuo (Department of nursing, Shinshu University Hospital)  
**信州大学医学部附属病院通院治療室で婦人科 TC 療法を受けた患者での、末梢神経障害に対する冷却法の実態調査**  
 松尾 麻衣子 (信州大学医学部附属病院 看護部)
- P104-2 **Analysis of response to symptom in patients with chemotherapy-induced peripheral neuropathy (CIPN)**  
 Kayo Ozaki (out-patient chemotherapy center)  
**がん薬物療法による末梢神経障害に対する患者の症状体験の検討**  
 尾崎 香代 (熊本大学病院 外来化学療法センター)
- P104-3 **Quality of life and related factors in head and neck cancer patients undergoing radiation therapy: A literature review**  
 Kumi Suzuki (Faculty of Nursing)  
**放射線療法を受けている頭頸部がん患者の Quality of Life の変化と関連要因：文献レビュー**  
 鈴木 久美 (大阪医科薬科大学看護学部)
- P104-4 **Unmet care needs and quality of life in patients with advanced gastrointestinal cancer with immune checkpoint inhibitors**  
 Aki Ueyama (former Keio University Hospital)  
**免疫チェックポイント阻害薬の治療を受けた進行消化器がん患者のアンメットケアニーズと生活の質：横断研究**  
 上山 昌 (前慶應義塾大学病院)
- P104-5 **A survey on the life of post-discharge in patients receiving peptide receptor radionuclide therapy (PRRT)**  
 Yuho Yoshimoto (Osaka International Cancer Institute)  
**ペプチド受容体放射線核種治療を受けた患者の退院後の療養生活に関する実態調査**  
 吉本 有穂 (大阪国際がんセンター 看護部)
- P104-6 **The effect of the first pre-examination interview by a nurse for patients scheduled for radiation therapy**  
 Kunie Koiwai (gairai)  
**放射線治療予定患者を対象とした看護師による初回診察前面談の効果～患者アンケート調査による不安軽減と意思決定支援についての評価～**  
 古岩井 邦江 (公立西知多総合病院)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P104-7	<b>Orientation Using the Original DVDs Can Explain Efficiently and Save Time</b> Kana Ishida (nursing department) <b>DVDを使用した外来化学療法室オリエンテーションの試み</b> 石田 夏菜 (中濃厚生病院)
P104-8	<b>演題取下</b>
13:05-13:50 Poster Session 105	
<b>P105</b>	<b>Multidisciplinary Team Program 7 (Other)</b> 多職種連携プログラム7 (その他)
P105-1	<b>Strategy for community hospitals to function as cancer genome medical collaborative hospitals</b> Yuka Kobayashi (Nagaoka Chuo General Hospital Department of Clinical Oncology) <b>市中病院がゲノム連携病院として稼働するための戦略</b> 小林 由夏 (長岡中央総合病院 腫瘍内科)
P105-2	<b>Study of patients who died within 30 days of the CGP registration date</b> Ryuji Hayashi (Toyama University Hospital) <b>がん遺伝子パネル検査登録後 30 日以内に死亡した症例の検討</b> 林 龍二 (富山大学附属病院)
P105-3	<b>Improvement of treatment access based on comprehensive genomic profiling tests at our local hospital</b> Takuya Tsujimura (Tenri Hospital) <b>当院におけるがん遺伝子パネル検査に基づく治療への到達率改善の取り組み</b> 辻村 拓也 (天理よろづ相談所病院)
P105-4	<b>Anti-cancer drug exposure survey at Niigata City General Hospital</b> Ryuhei Hada (Department of pharmacy) <b>新潟市民病院における抗がん剤曝露調査</b> 羽田 竜平 (新潟市民病院 薬剤部)
P105-5	<b>Two cases of prostate cancer who were referred to a rehabilitation ward after suffering lumbar compression fractures</b> Noritaka Yamaguchi (SHIN-YOKOHAMA REHABILITATION HOSPITAL) <b>骨脆弱性による腰椎圧迫骨折後に回復期リハビリテーション病棟に紹介された前立腺癌患者 2 例の検討</b> 山口 法隆 (新横浜リハビリテーション病院)
P105-6	<b>Actual condition survey of home visiting chemotherapy by Subspecialty Boards of Medical Oncology, JSMO</b> Nobuhiro Tsuruta (Tsuruta clinic) <b>JSMO がん薬物療法専門医による訪問化学療法の実態報告</b> 鶴田 展大 (鶴田クリニック)
P105-7	<b>Development of a program to overcome grief and promote resilience among nurses involved in end-of-life cancer care</b> Masako Nakamura (Nursing) <b>終末期がん看護に携わる看護師の悲嘆を乗り越える回復力を促進するプログラムの開発</b> 中村 正子 (京都看護大学)

P105-8 **Activity report on the introduction of PBL from the perspective of medical students for first-year medical students**

Banri Tsuda (Department of Palliative Medicine, Tokai University School of Medicine)

**医学科 1 年生を対象とした医学生目線の PBL 導入の活動報告**

津田 万里 (東海大学 医学部 専門診療学系 緩和医療学)

P105-9 **Survey of brand-name anticancer drug prescriptions to ascertain the impact of Patient Choice Services**

Seiichi Osaki (NHO Kanmon Medical Center)

**後発医薬品のある先発医薬品の選定療養に向けた抗がん薬使用状況調査報告**

尾崎 誠一 (国立病院機構 関門医療センター)

## Educational Lecture / 教育講演 (オンデマンド配信のみ)

### Educational Lecture 1 / 教育講演 1

**EL1** Basic for tumor biology  
腫瘍生物学の基礎 I, II

#### EL1 Basic for tumor biology

Tatsuhiko Shibata (Laboratory of Molecular Medicine, The Institute of Medical Science, The University of Tokyo)

**腫瘍生物学の基礎 I, II**

柴田 龍弘 (東京大学 医科学研究所 ゲノム医科学分野)

### Educational Lecture 2 / 教育講演 2

**EL2** Considering cancer immunity through changes in gut microbiota  
腸内細菌から考えるがん免疫

#### EL2 Considering cancer immunity through changes in gut microbiota

Kiyoshi Yoshimura (Department of Clinical Immuno Oncology, Clinical Research Institute of Clinical Pharmacology and Therapeutics, Showa University)

**腸内細菌から考えるがん免疫**

吉村 清 (昭和大学 臨床薬理研究所 臨床免疫腫瘍学部門)

### Educational Lecture 3 / 教育講演 3

**EL3** General remarks Chemotherapy / Chemotherapeutic agents  
薬物療法総論 I: 殺細胞性抗がん薬

#### EL3 General remarks Chemotherapy / Chemotherapeutic agents

Hiroki Ueda (Department of Medical Oncology, Kaizuka City Hospital)

**薬物療法総論 I: 殺細胞性抗がん薬**

上田 弘樹 (市立貝塚病院 腫瘍内科)

### Educational Lecture 4 / 教育講演 4

**EL4** Anti-Cancer Drug II: Molecular-Targeted Agents  
薬物療法総論 II: 分子標的薬剤

#### EL4 Anti-Cancer Drug II: Molecular-Targeted Agents

Hidetoshi Hayashi (Department of Medical Oncology, Kindai University Faculty of Medicine)

**薬物療法総論 II: 分子標的薬剤**

林 秀敏 (近畿大学医学部 内科学腫瘍内科)

### Educational Lecture 5 / 教育講演 5

**EL5** General Theory of Drug Therapy III: Immune Checkpoint Inhibitors  
薬物療法総論 III: 免疫チェックポイント阻害薬

#### EL5 General Theory of Drug Therapy III: Immune Checkpoint Inhibitors

Shigehisa Kitano (The Cancer Institute Hospital of JFCR)

**薬物療法総論 III: 免疫チェックポイント阻害薬**

北野 滋久 (がん研究会有明病院)



---

## Educational Lecture 6 / 教育講演 6

---

**EL6** Cancer Supportive Care and Adverse Event Management  
がん支持医療と有害事象対策

- EL6** **Cancer Supportive Care and Adverse Event Management**  
Tateaki Naito (Cancer Supportive Care Center/Division of Thoracic Oncology, Shizuoka Cancer Center)  
**がん支持医療と有害事象対策**  
内藤 立暁 (静岡県立静岡がんセンター 支持療法センター / 呼吸器内科)

---

## Educational Lecture 7 / 教育講演 7

---

**EL7** Oncologic Emergency & Paraneoplastic Syndrome  
オンコロジックエマージェンシーと腫瘍随伴症候群

- EL7** **Oncologic Emergency & Paraneoplastic Syndrome**  
Hiroaki Ikushima (Department of Respiratory Medicine, The University of Tokyo Hospital)  
**オンコロジックエマージェンシーと腫瘍随伴症候群**  
生島 弘彬 (東京大学医学部附属病院)

---

## Educational Lecture 8 / 教育講演 8

---

**EL8** Personalized Treatment and Geriatric Assessment in Older Cancer Patients  
高齢者のがん治療

- EL8** **Personalized Treatment and Geriatric Assessment in Older Cancer Patients**  
Yukari Tsubata (Department of Respiriology, Graduate School of Medicine, Gifu University)  
**高齢者のがん治療**  
津端 由佳里 (岐阜大学大学院医学系研究科 呼吸器内科)

---

## Educational Lecture 9 / 教育講演 9

---

**EL9** Knowledge about neuropathic pain  
神経障害性疼痛を知る

- EL9** **Knowledge about neuropathic pain**  
Tomohiro Nishi (Medical Oncology, Kawasaki Municipal Ida Hospital)  
**神経障害性疼痛を知る**  
西 智弘 (川崎市立井田病院 腫瘍内科)

---

## Educational Lecture 10 / 教育講演 10

---

**EL10** Psycho-oncology / Advanced Care Planning  
サイコオンコロジー・ACP(Advanced Care Planning)

- EL10** **Psycho-oncology / Advanced Care Planning**  
Nobuya Akizuki (Department of Psycho-Oncology / Psychiatry, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital)  
**サイコオンコロジー・ACP(Advanced Care Planning)**  
秋月 伸哉 (がん・感染症センター都立駒込病院 精神腫瘍科・メンタルクリニック)

---

## Educational Lecture 11 / 教育講演 11

---

**EL11** Overview of new anti-cancer drug development (Phase I, II, and III trials) and emerging topics  
抗悪性腫瘍薬における薬剤開発 (第 1、2、3 相試験) の概要と最近のトレンド

**EL11** **Overview of new anti-cancer drug development (Phase I, II, and III trials) and emerging topics**

Takafumi Koyama (National Cancer Center Hospital)

**抗悪性腫瘍薬における薬剤開発 (第 1、2、3 相試験) の概要と最近のトレンド**  
小山 隆文 (国立がん研究センター中央病院)

---

## Educational Lecture 12 / 教育講演 12

---

**EL12** Head and Neck Cancer · Thyroid Cancer  
頭頸部癌・甲状腺癌

**EL12** **Head and Neck Cancer · Thyroid Cancer**

Tomohiro Enokida (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)

**頭頸部癌・甲状腺癌**

榎田 智弘 (国立がん研究センター東病院 頭頸部内科)

---

## Educational Lecture 13 / 教育講演 13

---

**EL13** Esophageal and Gastric cancer  
食道癌・胃癌

**EL13** **Esophageal and Gastric cancer**

Satoshi Yuki (Department of Gastroenterology and Hepatology, Hokkaido University Hospital)

**食道癌・胃癌**

結城 敏志 (北海道大学病院 消化器内科)

---

## Educational Lecture 14 / 教育講演 14

---

**EL14** The current standard chemotherapy for Colon cancer and small bowel cancer  
大腸癌・小腸癌に対する薬物療法 ~ガイドライン update ~

**EL14** **The current standard chemotherapy for Colon cancer and small bowel cancer**

Atsuo Takashima (National Cancer Center Hospital)

**大腸癌・小腸癌に対する薬物療法 ~ガイドライン update ~**

高島 淳生 (国立がん研究センター中央病院)

---

## Educational Lecture 15 / 教育講演 15

---

**EL15** Multidisciplinary treatment for hepatocellular carcinoma  
肝細胞癌に対する集学的治療

**EL15** **Multidisciplinary treatment for hepatocellular carcinoma**

Kazuomi Ueshima (Kindai University Faculty of Medicine)

**肝細胞癌に対する集学的治療**

上嶋 一臣 (近畿大学病院)

---

## Educational Lecture 16 / 教育講演 16

---

**EL16** Current status of chemotherapy in Hepato-biliary and Pancreatic Cancer  
肝・胆道癌治療の現況

**EL16** **Current status of chemotherapy in Hepato-biliary and Pancreatic Cancer**  
Tatsuya Ioka (Yamaguchi University Hospital)

**肝・胆道癌治療の現況**

井岡 達也 (山口大学医学部附属病院)

---

## Educational Lecture 17 / 教育講演 17

---

**EL17** Small cell lung cancer and malignant mesothelioma  
小細胞肺癌・中皮腫

**EL17** **Small cell lung cancer and malignant mesothelioma**  
Kiichiro Ninomiya (Center for Comprehensive Genomic Medicine, Okayama University Hospital)

**小細胞肺癌・中皮腫**

二宮 貴一朗 (岡山大学病院 ゲノム医療総合推進センター)

---

## Educational Lecture 18 / 教育講演 18

---

**EL18** Overview of the development in the treatment for non-small cell lung cancer in 2024  
非小細胞肺癌治療の進歩 2024

**EL18** **Overview of the development in the treatment for non-small cell lung cancer in 2024**

Satoru Miura (Niigata Cancer Center Hospital)

**非小細胞肺癌治療の進歩 2024**

三浦 理 (新潟県立がんセンター新潟病院)

---

## Educational Lecture 19 / 教育講演 19

---

**EL19** Drug therapy for early-stage breast cancer  
乳癌周術期薬物療法

**EL19** **Drug therapy for early-stage breast cancer**

Fumikata Hara (Aichi Cancer Center)

**乳癌周術期薬物療法**

原文堅 (愛知県がんセンター)

---

## Educational Lecture 20 / 教育講演 20

---

**EL20** Breast cancer (management for recurrent breast cancer)  
乳がん (転移・再発薬物療法)

**EL20** **Breast cancer (management for recurrent breast cancer)**

Yoichi Naito (Department of General Internal Medicine, National Cancer Center Hospital East)

**乳がん (転移・再発薬物療法)**

内藤 陽一 (国立がん研究センター東病院)

---

---

## Educational Lecture 21 / 教育講演 21

---

**EL21** The up to date of chemotherapy for cervical cancer and endometrial cancer  
子宮頸癌ならびに子宮体癌における最新の薬物療法

EL21 **The up to date of chemotherapy for cervical cancer and endometrial cancer**

Tadaaki Nishikawa (The Jikei University School of Medicine)

**子宮頸癌ならびに子宮体癌における最新の薬物療法**

西川 忠曉 (東京慈恵会医科大学附属病院)

---

## Educational Lecture 22 / 教育講演 22

---

**EL22** Standard Treatment for Ovarian Cancer  
卵巣癌に対する標準治療

EL22 **Standard Treatment for Ovarian Cancer**

Kenichi Harano (Department of Experimental Therapeutics/ Medical Oncology, National Cancer Center Hospital East)

**卵巣癌に対する標準治療**

原野 謙一 (国立がん研究センター東病院 先端医療科 / 腫瘍内科)

---

## Educational Lecture 23 / 教育講演 23

---

**EL23** Systemic therapy for genitourinary cancers  
泌尿器がん (腎、尿路上皮、前立腺)

EL23 **Systemic therapy for genitourinary cancers**

Hiroshi Kitamura (Department of Urology, Faculty of Medicine, University of Toyama)

**泌尿器がん (腎、尿路上皮、前立腺)**

北村 寛 (富山大学学術研究部医学系 腎泌尿器科学)

---

## Educational Lecture 24 / 教育講演 24

---

**EL24** bone and soft tissue sarcomas  
骨軟部腫瘍

EL24 **bone and soft tissue sarcomas**

Yu Oyama (Department of Medical Oncology, Kameda Medical Center)

**骨軟部腫瘍**

大山 優 (亀田総合病院 腫瘍内科)

---

## Educational Lecture 25 / 教育講演 25

---

**EL25** Guideline for bone metastases  
転移性骨腫瘍の診療ガイドライン

EL25 **Guideline for bone metastases**

Hiroyuki Shibata (Department of Clinical Oncology, Akita University Graduate School of Medicine)

**転移性骨腫瘍の診療ガイドライン**

柴田 浩行 (秋田大学大学院医学系研究科 臨床腫瘍学講座)

---

---

## Educational Lecture 26 / 教育講演 26

---

**EL26** Malignant lymphomas - updated treatment strategy  
悪性リンパ腫の治療体系

- EL26 **Malignant lymphomas - updated treatment strategy**  
Daisuke Ennishi (Center for Comprehensive Genomic Medicine, Okayama University Hospital)  
**悪性リンパ腫の治療体系**  
遠西 大輔 (岡山大学病院ゲノム医療総合推進センター)

---

## Educational Lecture 27 / 教育講演 27

---

**EL27** Current Clinical Practice for Leukemia in Japan  
本邦における白血病診療

- EL27 **Current Clinical Practice for Leukemia in Japan**  
Kimikazu Yakushijin (Department of Medical Oncology and Hematology, Kobe University Hospital)  
**本邦における白血病診療**  
葉師神 公和 (神戸大学医学部附属病院 腫瘍・血液内科)

---

## Educational Lecture 28 / 教育講演 28

---

**EL28** 2025 treatment algorithm for multiple myeloma- every year a new standard -  
多発性骨髄腫治療アルゴリズム 2025 ~ every year a new standard ~

- EL28 **2025 treatment algorithm for multiple myeloma- every year a new standard -**  
Yuichiro Nawa (Division of Hematology, Ehime Prefectural Central Hospital)  
**多発性骨髄腫治療アルゴリズム 2025 ~ every year a new standard ~**  
名和 由一郎 (愛媛県立中央病院 血液内科)

---

## Educational Lecture 29 / 教育講演 29

---

**EL29** NEN (neuroendocrine neoplasms), GIST (gastrointestinal stromal tumor)  
神経内分泌腫瘍 (NEN; neuroendocrine neoplasms) ・消化管間質腫瘍 (GIST; gastrointestinal stromal tumor)

- EL29 **NEN (neuroendocrine neoplasms), GIST (gastrointestinal stromal tumor)**  
Katsunori Shinozaki (Division of Clinical Oncology, Hiroshima Prefectural Hospital)  
**神経内分泌腫瘍 (NEN; neuroendocrine neoplasms) ・消化管間質腫瘍 (GIST; gastrointestinal stromal tumor)**  
篠崎 勝則 (県立広島病院 臨床腫瘍科)

---

## Educational Lecture 30 / 教育講演 30

---

**EL30** Skin Cancer  
皮膚がん

- EL30 **Skin Cancer**  
Aya Nishizaki (Tokyo Metropolitan Cancer and Infectious Diseases center Komagome Hospital)  
**皮膚がん**  
西澤 綾 (東京都立駒込病院)

---

## Educational Lecture 31 / 教育講演 31

---

**EL31** Cancer of Unknown Primary - A Practical Approach to Diagnosis and Treatment -  
原発不明癌—診断・治療の実践的なアプローチ方法—

EL31 **Cancer of Unknown Primary - A Practical Approach to Diagnosis and Treatment -**  
Junko Tanizaki (Department of Medical Oncology, Kindai University Faculty of Medicine)

原発不明癌—診断・治療の実践的なアプローチ方法—

谷崎 潤子 (近畿大学医学部内科学教室 腫瘍内科部門)

---

## Educational Lecture 32 / 教育講演 32

---

**EL32** Pediatric tumor  
小児腫瘍

EL32 **Pediatric tumor**  
Motohiro Kato (Department of Pediatrics, the University of Tokyo)

小児腫瘍

加藤 元博 (東京大学医学部附属病院)

---

## Educational Lecture 33 / 教育講演 33

---

**EL33** Precision Oncology in Japan  
がんゲノム医療

EL33 **Precision Oncology in Japan**  
Kuniko Sunami (National Cancer Center Hospital)

がんゲノム医療

角南 久仁子 (国立がん研究センター中央病院)

---

## Educational Lecture 34 / 教育講演 34

---

**EL34** Primary and metastatic brain tumors  
原発性脳腫瘍・転移性脳腫瘍

EL34 **Primary and metastatic brain tumors**  
Yukihiko Sonoda (Department of Neurological Surgery, Faculty of Medicine, Yamagata University)

原発性脳腫瘍・転移性脳腫瘍

園田 順彦 (山形大学 医学部 脳神経外科)

---

## Educational Lecture 35 / 教育講演 35

---

**EL35** Clinical trials act / Personal Data Protection / Conflict of interest  
臨床研究法・個人情報保護・利益相反

EL35 **Clinical trials act / Personal Data Protection / Conflict of interest**  
Katsuyuki Hotta (Okayama University Hospital)

臨床研究法・個人情報保護・利益相反

堀田 勝幸 (岡山大学病院)

---